var title_f18_32_18944="Dry AMD w pigment mottling";
var content_f18_32_18944=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F70148&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F70148&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dry type age-related macular degeneration (AMD) with drusen and pigmentary mottling",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 351px; height: 291px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An area of pigmentary mottling is evident beneath the retina (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from the Massachusetts Eye &amp; Ear Infirmary, Photographer, David Walsh.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_32_18944=[""].join("\n");
var outline_f18_32_18944=null;
var title_f18_32_18945="Hemorrhagic edema infancy";
var content_f18_32_18945=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61173&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61173&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Acute hemorrhagic edema of infancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 409px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Lawrence Zemel, MD. Connecticut Children's Medical Center. Copyright &copy; Lawrence Zemel, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_32_18945=[""].join("\n");
var outline_f18_32_18945=null;
var title_f18_32_18946="Port wine stain - V2 infant";
var content_f18_32_18946=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Port wine stain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A port wine stain in the V2 distribution is present on the face of this infant.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_32_18946=[""].join("\n");
var outline_f18_32_18946=null;
var title_f18_32_18947="Electrograms ventricular tachy";
var content_f18_32_18947=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intracardiac electrograms during ventricular tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 283px; height: 345px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During an episodes of sustained monomorphic ventricular tachycardia (VT) a recording from the left ventricle (LV) shows complex, fragmented local electrograms. One of the components is a low amplitude, high frequency mid-diastolic potential (MDP) (arrows), which are isolated from the other components by isoelectric segments. The presence of this MDP identifies a target for radiofrequency ablation, although validation with other mapping techniques is necessary.",
"    <div class=\"footnotes\">",
"     V: ventricular electrogram.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_32_18947=[""].join("\n");
var outline_f18_32_18947=null;
var title_f18_32_18948="Penicillin V potassium: Patient drug information";
var content_f18_32_18948=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Penicillin V potassium: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/46/23269?source=see_link\">",
"     see \"Penicillin V potassium: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/52/15172?source=see_link\">",
"     see \"Penicillin V potassium: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F207857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Pen VK&reg;;",
"     </li>",
"     <li>",
"      Novo-Pen-VK;",
"     </li>",
"     <li>",
"      Nu-Pen-VK",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702700",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to penicillin V potassium, any penicillin, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699436",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (solution) in a refrigerator. Throw away any part not used after 2 weeks.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10960 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-199.231.185.123-B6CE745EC8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_32_18948=[""].join("\n");
var outline_f18_32_18948=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207857\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018197\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018196\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018201\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018202\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018204\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018199\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018200\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018205\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018206\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/46/23269?source=related_link\">",
"      Penicillin V potassium: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/52/15172?source=related_link\">",
"      Penicillin V potassium: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_32_18949="Solitary keratoacanthoma";
var content_f18_32_18949=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F73408&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F73408&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Keratoacanthoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A dome-shaped nodule with keratotic core is present on the skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_32_18949=[""].join("\n");
var outline_f18_32_18949=null;
var title_f18_32_18950="Computed tomography of the hepatobiliary tract";
var content_f18_32_18950=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Computed tomography of the hepatobiliary tract",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/32/18950/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/32/18950/contributors\">",
"     Umaprasanna S Karnam, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/32/18950/contributors\">",
"     Jonathan B Kruskal, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/32/18950/contributors\">",
"     K Rajender Reddy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/32/18950/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/32/18950/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/32/18950/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/32/18950/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/32/18950/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) can be used to image the hepatobiliary system, with perhaps the exception of the gallbladder, which is better imaged with ultrasound. Magnetic resonance cholangiopancreatography (MRCP) is superior to CT for evaluating the biliary tract, but CT is useful for hepatic imaging and in cases where it is not clear whether a problem is originating in the liver, gallbladder, or bile ducts. CT, like magnetic resonance imaging (MRI), allows for a more thorough evaluation of the liver and other abdominal structures than ultrasound, and is less dependent upon operator skills. In contrast to ultrasound, successful CT of the liver can be obtained despite obesity, overlying bowel gas, or ascites.",
"   </p>",
"   <p>",
"    This topic review will discuss some general principles of CT as it applies to imaging of the hepatobiliary system. A more complete discussion of the technique of CT scanning, MRCP, and hepatobiliary ultrasound can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17032?source=see_link\">",
"     \"Principles of computed tomography of the chest\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23351?source=see_link\">",
"     \"Magnetic resonance cholangiopancreatography\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21992?source=see_link\">",
"     \"Ultrasonography of the hepatobiliary tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A CT scan is created by passing fine x-ray beams through the patient, with rotating detectors located on the opposite side of the body to record the amount of radiation not attenuated by the tissues being imaged. This information is then processed by a computer that calculates the attenuation values with reference to a standard water value of 0 Hounsfield units.",
"   </p>",
"   <p>",
"    Intravenous iodinated contrast material is used to opacify vessels, and to determine the vascularity of lesions relative to that of normal liver parenchyma. The timing of image acquisition is crucial in hepatic imaging; images should be obtained during an interval of sustained hepatic enhancement before the equilibrium phase is reached (",
"    <a class=\"graphic graphic_algorithm graphicRef72112 \" href=\"UTD.htm?0/38/622\">",
"     algorithm 1",
"    </a>",
"    ). At equilibrium, lesions may become isodense with the liver parenchyma and therefore not visible.",
"   </p>",
"   <p>",
"    Conventional CT scanners obtain a series of individual scans during suspended respiration. This incremental table-patient transport results in respiratory misregistration due to varying breath-holds during scans. Thus, anatomic fields may be omitted and data lost. Conventional CT scan is less sensitive than ultrasound in detecting hepatic lesions smaller than 1 to 2 cm. It is also more expensive, and involves the risks associated with radiation exposure and intravenous contrast material. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31305?source=see_link\">",
"     \"Immediate hypersensitivity reactions to radiocontrast media: Clinical manifestations, diagnosis, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dynamic CT involves the rapid infusion of intravenous contrast during incremental scanning of the liver; the contrast produces a sustained enhancement of the hepatic parenchyma (portal phase) for a one- to two-minute period during which all images must be obtained. Arterial phase enhancement cannot be obtained because of delays inherent in contrast administration and table motion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Contrast material",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delivery of intravenous contrast material may be as a bolus or continuous infusion in a biphasic or uniphasic manner. Hepatic enhancement depends upon the injected iodine load relative to body weight. Most protocols aim to deliver 42 to 50 g of iodine since patients with normal preexistent renal function have no change in serum creatinine levels for one to seven days after a 50 g iodine load.",
"   </p>",
"   <p>",
"    Images are acquired during well-documented pharmacokinetic enhancement phases (vascular, redistribution, or equilibrium) depending upon the specific tumor or perfusion abnormality being evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18950/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Images are acquired during the vascular phase to document tumor vascularity, arterial patency, and blood supply; this is most useful to identify lesions such as hepatocellular carcinoma [",
"      <a class=\"abstract\" href=\"UTD.htm?18/32/18950/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Images are acquired during the redistribution phase when portal opacification has reached a maximal level; this is most useful to identify lesions such as colorectal cancer metastases [",
"      <a class=\"abstract\" href=\"UTD.htm?18/32/18950/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Images rarely are acquired during the equilibrium phase to look for markedly delayed retention of contrast material within fibrous tumorous or scarring. Homogenous delayed enhancement is suggestive of cholangiocarcinoma [",
"      <a class=\"abstract\" href=\"UTD.htm?18/32/18950/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Common hepatic protocols administer contrast material at 3",
"    <span class=\"nowrap\">",
"     mL/sec",
"    </span>",
"    for 50 to 60 seconds and acquire images at 20 seconds (vascular phase) and 60 seconds (portal venous or redistribution phase) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18950/abstract/1\">",
"     1",
"    </a>",
"    ]. If needed, equilibrium images are obtained after 10 to 20 minutes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Potential technical problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of technical errors can compromise the quality of hepatic images obtained on CT scan:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Insufficient amount of contrast (optimal hepatic imaging requires approximately 2",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of contrast material)",
"     </li>",
"     <li>",
"      Insufficient rate of infusion (optimal hepatic imaging requires at least 3 to 5",
"      <span class=\"nowrap\">",
"       mL/sec",
"      </span>",
"      infusion of contrast material)",
"     </li>",
"     <li>",
"      Improper time-sequence of obtaining different phases",
"     </li>",
"     <li>",
"      Use of non-helical scanner (see below)",
"     </li>",
"     <li>",
"      Use of thick CT cuts (&gt;7 mm; optimal sections are 2.5 to 7 mm)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     HELICAL (SPIRAL) CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The latest generation of CT scanners is helical or spiral CT scanning. This technique was developed to optimize detection and characterization of lesions that may be missed by conventional incremental contrast-enhanced CT [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18950/abstract/3\">",
"     3",
"    </a>",
"    ]. The x-ray focus describes a spiral or helical path around the patient, allowing a more rapid and complete image acquisition. An entire liver can be imaged during a single breath-hold, thereby reducing artifacts due to nonuniform breathing. In addition, images can be obtained during both the arterial and portal venous phases, the so-called double helix study. A volume of data is collected and axial slices are reconstructed at any selected thicknesses within the scanned volume [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18950/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Multiplanar and three-dimensional images can be reformatted from the source data set.",
"   </p>",
"   <p>",
"    Helical technology also permits single level multiscan or continuous data acquisition at a single anatomical level. In the liver this is used for lesion characterization and plays a diagnostic role in identifying hemangiomas and vascular metastases. Thus, helical CT is superior to conventional CT for detecting and characterizing the vascularity of liver tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18950/abstract/3\">",
"     3",
"    </a>",
"    ]. It should be utilized in patients known or suspected to have hypervascular neoplasms such as hepatocellular carcinoma, metastases from renal cell carcinoma, neuroendocrine (islet cell) tumors, breast cancer, melanoma, thyroid carcinoma, and sarcomas [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18950/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 21 patients with hepatic neoplasms (12 with primary hepatic tumors and 9 with metastases) the sensitivity of helical CT was 91 percent for nodules greater than 1 cm and 56 percent for nodules 1 cm or less [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18950/abstract/5\">",
"     5",
"    </a>",
"    ]. False positive findings occurred in 4 percent of lesions. These results compare favorably with the more invasive CT arterial portography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CT ARTERIAL PORTOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT arterial portography (CTAP) was used for the detection of intrahepatic tumors and portal vein obstruction, but because of its invasive nature and the improved resolution of the newest multi-row CT scanners, it is seldom used any longer in practice. CTAP involves portal enhancement of the liver by infusion of contrast material via an angiographically placed catheter in the superior mesenteric artery, providing good delineation of intrahepatic vessels and the hepatic parenchyma. Since most liver tumors receive an arterial blood supply, this technique enhances differences between the normal parenchyma and most liver lesions.",
"   </p>",
"   <p>",
"    A variety of conditions can give false positive images, including areas of fibrosis, focal steatosis, regenerative nodules, coexisting benign tumors (cyst, hemangiomas), physiologic variations, and subcapsular hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18950/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. This is a problem particularly in patients with cirrhosis and portal hypertension, a significant issue since these are the patients at highest risk for the development of hepatocellular carcinomas.",
"   </p>",
"   <p>",
"    False negative CTAP is a problem in patients with cirrhosis and portal hypertension. False negatives are much less common than false positives, but can be seen with capsular and subcapsular metastases, peritoneal carcinomatosis, adenopathy, and lesions &lt;2 cm. In addition, studies are technically inadequate in up to 26 percent of cases.",
"   </p>",
"   <p>",
"    Helical CT is now being used to perform CTAP, which reduces respiratory motion artifacts, allows for image acquisition during peak lesion enhancement, and allows reconstruction of images at arbitrary intervals to better center the sections over focal lesions. This technique has been reported to have a very high detection rate for hepatic metastases from colorectal cancer. Dual phase CTAP (phase 1-scanning first 30 to 35 seconds after the administration of the contrast injections, phase 2 beginning 10 to 18 seconds after the end of phase 1) has a better detection rate for small (&lt;2 cm) hepatomas compared with single phase CTAP.",
"   </p>",
"   <p>",
"    Helical CTAP is currently the most accurate diagnostic modality for hepatocellular carcinoma and other hypervascular liver tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18950/abstract/10\">",
"     10",
"    </a>",
"    ]. Given the invasive nature of this procedure, it is usually reserved for the following settings: when there is a strong clinical suspicion for HCC despite negative results on other imaging modalities and when the results of therapy would be altered based upon the detection of additional tumor foci [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18950/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. In many cases, MRI has taken over the role when subtle liver findings require further characterization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     LIPIODOL-ENHANCED CT SCAN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipiodol (iodized poppy seed oil) concentrates selectively in hepatic tumors, primarily hepatocellular carcinoma. Delayed CT imaging after 7 to 14 days reveals the oil-based contrast agent in the tumor, but not in normal hepatic parenchyma. Because Lipiodol is selectively concentrated in tumor tissue, it is used in intra-arterial chemoembolization regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18950/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36138?source=see_link\">",
"     \"Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aside from the importance of CT for detecting hepatic tumors discussed above, this section will briefly describe some of the other major clinical uses of CT in patients with suspected hepatobiliary disease. The use of CT and other imaging studies in the individual disorders is discussed in detail on the appropriate topic reviews.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CT or ultrasound can be used in the initial evaluation of the patient with obstructive jaundice, although CT allows a more thorough evaluation of structures outside the biliary tree, including the pancreas, portal and retroperitoneal lymph nodes, and vascular structures [",
"      <a class=\"abstract\" href=\"UTD.htm?18/32/18950/abstract/12\">",
"       12",
"      </a>",
"      ]. When used with contrast agents excreted into the biliary system, CT cholangiography accurately depicts biliary anatomy and has been used for the workup of living donor candidates for right lobe transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?18/32/18950/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/50/42790?source=see_link&amp;anchor=H7#H7\">",
"       \"Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia\", section on 'Helical CT scan'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Contrast enhanced CT is the procedure of choice to evaluate the abdomen and pelvis in patients who present with abdominal trauma. The scans can be performed quickly in relatively unstable patients, and large areas can be visualized while the patient holds a few breaths. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=see_link&amp;anchor=H10#H10\">",
"       \"Initial evaluation and management of blunt abdominal trauma in adults\", section on 'Computed tomography'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      CT can be used to detect liver abscess; it is better than ultrasound for identifying small abscesses, extrahepatic fluid collections, and air and calcification. It is usually not possible to differentiate a tumor from abscess; biopsy or aspiration may be needed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29526?source=see_link&amp;anchor=H7#H7\">",
"       \"Pyogenic liver abscess\", section on 'Imaging'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Budd-Chiari syndrome arises from the segmental or global obstruction of hepatic venous outflow. The CT scan may identify the cause of obstruction, but is most likely to depict changes secondary to venous occlusion such as ascites and hepatic enlargement, especially in the caudate lobe. Intravenous contrast material must be used to demonstrate the characteristic patchy central enhancement with poor peripheral enhancement, and absence of contrast material in one or more of the hepatic veins. In chronic cases, the hepatic veins are usually not visualized, the caudate lobe is enlarged and enhanced, and the portal vein is patent. CT is not a useful technique for depicting the direction of flow in the portal vein, which may be reversed in patients with Budd Chiari; this will be best depicted on ultrasound using color flow and Doppler. Additional findings that may be identified include the cause of venous occlusion, such as tumor growth into the hepatic vein (hepatoma, colorectal metastases, atrial myxoma, renal cell carcinoma, adrenal carcinoma), thrombus in the hepatic vein, constrictive pericarditis, or right heart failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3434?source=see_link&amp;anchor=H9#H9\">",
"       \"Clinical manifestations, diagnosis, and treatment of the Budd-Chiari syndrome\", section on 'CT scan'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      CT is a useful technique for guiding fluid aspiration and drainage from the peritoneal cavity. However, the technique does not provide real-time image guidance and may therefore not identify a peristalsing loop of bowel entering the field to be aspirated. Time, lack of portability, and radiation exposure make ultrasound a superior technique for fluid aspiration.",
"     </li>",
"     <li>",
"      Multidetector CT permits high-resolution and high-speed helical imaging of the entire liver during a single breath hold and delineates fine vascular details [",
"      <a class=\"abstract\" href=\"UTD.htm?18/32/18950/abstract/14-16\">",
"       14-16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17032?source=see_link\">",
"       \"Principles of computed tomography of the chest\"",
"      </a>",
"      .) The precise three-dimensional relationship of the vasculature to the liver provides an explicit, non-invasive roadmap to the transplant surgeon. In addition, it also helps in identifying and characterizing liver lesions. Mild (&gt;25 percent), moderate (50 percent), and severe steatosis (&lt;75 percent) resulted in a drop of 6, 11, and 20 Hounsfield units of attenuation, respectively, when compared to normal liver [",
"      <a class=\"abstract\" href=\"UTD.htm?18/32/18950/abstract/15\">",
"       15",
"      </a>",
"      ]. This offers the potential to obtain a non-invasive diagnosis of fatty liver. Sophisticated software also makes it possible to quantitate lobar liver volume, to perform a virtual hepatectomy, and to determine if the graft can be safely placed in the recipient's abdominal cavity [",
"      <a class=\"abstract\" href=\"UTD.htm?18/32/18950/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62998097\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) can be used to image the hepatobiliary system, with perhaps the exception of the gallbladder, which is better imaged with ultrasound. Magnetic resonance cholangiopancreatography (MRCP) is superior to CT for evaluating the biliary tract, but CT is useful for hepatic imaging and in cases where it is not clear whether a problem is originating in the liver, gallbladder, or bile ducts. CT allows for a more thorough evaluation of the liver and other abdominal structures than ultrasound, is less dependent upon operator skills, and can be obtained despite obesity, overlying bowel gas, or ascites.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A CT scan is created by passing fine X-ray beams through the patient, with rotating detectors located on the opposite side of the body to record the amount of radiation not attenuated by the tissues being imaged. This information is then processed by a computer that calculates the attenuation values with reference to a standard water value of 0 Hounsfield units. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intravenous iodinated contrast material is used to opacify vessels and to determine the vascularity of lesions relative to that of normal liver parenchyma. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Contrast material'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A major role of hepatobiliary CT is in the evaluation of hepatic tumors. Helical CT is superior to conventional CT for detecting and characterizing the vascularity of liver tumors. It should be utilized in patients known or suspected to have hypervascular neoplasms such as hepatocellular carcinoma, metastases from renal cell carcinoma, neuroendocrine (islet cell) tumors, breast cancer, melanoma, thyroid carcinoma, and sarcomas. Magnetic resonance imaging is another modality used for the imaging of liver tumors. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Helical (spiral) CT'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28054?source=see_link\">",
"       \"Magnetic resonance imaging of the hepatobiliary tract\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      CT or ultrasound can be used in the initial evaluation of the patient with obstructive jaundice, although CT allows a more thorough evaluation of structures outside the biliary tree, including the pancreas, portal and retroperitoneal lymph nodes, and vascular structures. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/50/42790?source=see_link&amp;anchor=H7#H7\">",
"       \"Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia\", section on 'Helical CT scan'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Contrast enhanced CT is the procedure of choice to evaluate the abdomen and pelvis in patients who present with abdominal trauma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=see_link&amp;anchor=H10#H10\">",
"       \"Initial evaluation and management of blunt abdominal trauma in adults\", section on 'Computed tomography'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      CT can be used to detect liver abscess; it is better than ultrasound for identifying small abscesses, extrahepatic fluid collections, and air and calcification. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29526?source=see_link&amp;anchor=H7#H7\">",
"       \"Pyogenic liver abscess\", section on 'Imaging'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      CT scan may identify the cause of obstruction in patients with Budd-Chiari syndrome, but is most likely to depict changes secondary to venous occlusion such as ascites and hepatic enlargement, especially in the caudate lobe. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3434?source=see_link&amp;anchor=H9#H9\">",
"       \"Clinical manifestations, diagnosis, and treatment of the Budd-Chiari syndrome\", section on 'CT scan'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18950/abstract/1\">",
"      Baron RL. Understanding and optimizing use of contrast material for CT of the liver. AJR Am J Roentgenol 1994; 163:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18950/abstract/2\">",
"      Itai Y, Matsui O. Blood flow and liver imaging. Radiology 1997; 202:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18950/abstract/3\">",
"      Heiken JP, Brink JA, Vannier MW. Spiral (helical) CT. Radiology 1993; 189:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18950/abstract/4\">",
"      Oliver JH 3rd, Baron RL. Helical biphasic contrast-enhanced CT of the liver: technique, indications, interpretation, and pitfalls. Radiology 1996; 201:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18950/abstract/5\">",
"      Kuszyk BS, Bluemke DA, Urban BA, et al. Portal-phase contrast-enhanced helical CT for the detection of malignant hepatic tumors: sensitivity based on comparison with intraoperative and pathologic findings. AJR Am J Roentgenol 1996; 166:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18950/abstract/6\">",
"      Soyer P, Bluemke DA, Fishman EK. CT during arterial portography for the preoperative evaluation of hepatic tumors: how, when, and why? AJR Am J Roentgenol 1994; 163:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18950/abstract/7\">",
"      Ichikawa T, Ohtomo K, Takahashi S. Hepatocellular carcinoma: detection with double-phase helical CT during arterial portography. Radiology 1996; 198:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18950/abstract/8\">",
"      Takayasu K, Muramatsu Y, Furukawa H, et al. Early hepatocellular carcinoma: appearance at CT during arterial portography and CT arteriography with pathologic correlation. Radiology 1995; 194:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18950/abstract/9\">",
"      Irie T, Takeshita K, Wada Y, et al. CT evaluation of hepatic tumors: comparison of CT with arterial portography, CT with infusion hepatic arteriography, and simultaneous use of both techniques. AJR Am J Roentgenol 1995; 164:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18950/abstract/10\">",
"      Oliver JH 3rd, Baron RL, Federle MP, et al. Hypervascular liver metastases: do unenhanced and hepatic arterial phase CT images affect tumor detection? Radiology 1997; 205:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18950/abstract/11\">",
"      Merine D, Takayasu K, Wakao F. Detection of hepatocellular carcinoma: comparison of CT during arterial portography with CT after intraarterial injection of iodized oil. Radiology 1990; 175:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18950/abstract/12\">",
"      Gulliver DJ, Baker ME, Cheng CA, et al. Malignant biliary obstruction: efficacy of thin-section dynamic CT in determining resectability. AJR Am J Roentgenol 1992; 159:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18950/abstract/13\">",
"      Wang ZJ, Yeh BM, Roberts JP, et al. Living donor candidates for right hepatic lobe transplantation: evaluation at CT cholangiography--initial experience. Radiology 2005; 235:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18950/abstract/14\">",
"      Kamel IR, Raptopoulos V, Pomfret EA, et al. Living adult right lobe liver transplantation: imaging before surgery with multidetector multiphase CT. AJR Am J Roentgenol 2000; 175:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18950/abstract/15\">",
"      Raptopoulos V, Karellas A, Bernstein J, et al. Value of dual-energy CT in differentiating focal fatty infiltration of the liver from low-density masses. AJR Am J Roentgenol 1991; 157:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18950/abstract/16\">",
"      Kamel IR, Kruskal JB, Warmbrand G, et al. Accuracy of volumetric measurements after virtual right hepatectomy in potential donors undergoing living adult liver transplantation. AJR Am J Roentgenol 2001; 176:483.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 668 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-0C172D990F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_32_18950=[""].join("\n");
var outline_f18_32_18950=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H62998097\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Contrast material",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Potential technical problems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HELICAL (SPIRAL) CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CT ARTERIAL PORTOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      LIPIODOL-ENHANCED CT SCAN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL USE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H62998097\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/668\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/668|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?0/38/622\" title=\"algorithm 1\">",
"      CT hepatobiliary disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3434?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of the Budd-Chiari syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/50/42790?source=related_link\">",
"      Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31305?source=related_link\">",
"      Immediate hypersensitivity reactions to radiocontrast media: Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=related_link\">",
"      Initial evaluation and management of blunt abdominal trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23351?source=related_link\">",
"      Magnetic resonance cholangiopancreatography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28054?source=related_link\">",
"      Magnetic resonance imaging of the hepatobiliary tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36138?source=related_link\">",
"      Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17032?source=related_link\">",
"      Principles of computed tomography of the chest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29526?source=related_link\">",
"      Pyogenic liver abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21992?source=related_link\">",
"      Ultrasonography of the hepatobiliary tract",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_32_18951="Factitious hypoglycemia";
var content_f18_32_18951=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Factitious hypoglycemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/32/18951/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/32/18951/contributors\">",
"     F John Service, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/32/18951/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/32/18951/contributors\">",
"     Irl B Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/32/18951/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/32/18951/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/32/18951/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factitious (or factitial) hypoglycemia occurs secondary to the surreptitious use of insulin or insulin secretagogues (sulfonylureas, meglitinides). The term factitious (or factitial) hypoglycemia has been used in medical parlance to imply covert human activity. The consideration of such a possibility often changes the patient-clinician relationship, leading the clinician to feel deceived and the patient to feel mistrusted. However, the pejorative connotation with which factitious illness has been encumbered requires softening because some patients with factitious disease suffer through no fault of their own.",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, and treatment of factitious hypoglycemia will be reviewed here. Other causes of hypoglycemia are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44664?source=see_link\">",
"     \"Hypoglycemia in adults: Clinical manifestations, definition, and causes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12777?source=see_link\">",
"     \"Insulinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY OF FACTITIOUS HYPOGLYCEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factitious hypoglycemia results from the use of insulin or insulin secretagogues (sulfonylurea, meglitinides), but not from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    or other insulin sensitizing antidiabetic drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18951/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Ingestion of an oral insulin secretagogue",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first reported case of factitious hypoglycemia related to a sulfonylurea was due to the surreptitious self-administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/0/6151?source=see_link\">",
"     chlorpropamide",
"    </a>",
"    by a patient without diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18951/abstract/4\">",
"     4",
"    </a>",
"    ]. Inappropriate manipulation of hypoglycemic tablets by a patient with diabetes is another cause of factitious hypoglycemia.",
"   </p>",
"   <p>",
"    In addition to patients who knowingly take insulin secretagogue drugs, there are patients who, by taking a prescribed medication in good faith, have hypoglycemia because a sulfonylurea was mistakenly dispensed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18951/abstract/5\">",
"     5",
"    </a>",
"    ]. In most instances, confusion in dispensing the drug arose because of similarity in spelling between the intended medication and the sulfonylurea. The most common errors in early reports were the substitutions of Diabinese for Diamox [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18951/abstract/6,7\">",
"     6,7",
"    </a>",
"    ] and of Tolinase for Tolectin [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18951/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypoglycemia in an elderly person whose spouse is being treated with a hypoglycemic tablet is generally due to a mix-up in medication. It may also occur after ingestion of herbal products contaminated with sulfonylureas [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18951/abstract/9\">",
"     9",
"    </a>",
"    ]. As an example, hypoglycemia has been reported after ingestion of illegal sexual-enhancement drugs or herbal preparations (eg, Power 1 Walnut) contaminated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    in amounts ranging from 13 to 100 mg per tablet [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18951/abstract/9\">",
"     9",
"    </a>",
"    ]. In a case series from Singapore, seven patients who ingested such products were comatose secondary to prolonged neuroglycopenia, and four patients subsequently died.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Administration of insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Covert self-administration of insulin by a patient without diabetes and the inappropriate manipulation of insulin by a patient with diabetes are causes of factitious hypoglycemia.",
"   </p>",
"   <p>",
"    Administration of a hypoglycemic agent by a parent to a child is an insidious form of child abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18951/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. In previous cases, the alleged perpetrator was the patient's mother who had ready access to insulin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36104?source=see_link\">",
"     \"Munchausen syndrome by proxy (medical child abuse)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Insulin has also been used to attempt suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18951/abstract/12\">",
"     12",
"    </a>",
"    ]. A review of 97 published cases found that completed suicide occurred in 17 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18951/abstract/13\">",
"     13",
"    </a>",
"    ]. In most cases, those attempting suicide were insulin-treated patients with diabetes. There was equal gender distribution within this series and a wide distribution of age, ranging from 20 to 70 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL CHARACTERISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factitious hypoglycemia in nondiabetic patients who knowingly self-administer hypoglycemic agents or in diabetic patients who manipulate their doses for the purpose of causing hypoglycemia is more common in women, occurs most commonly in the third or fourth decades of life, and, among nondiabetic subjects, is often found in those in health-related occupations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18951/abstract/14-19\">",
"     14-19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Nondiabetic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nondiabetic subjects with factitious hypoglycemia can present with a clinical syndrome that appears similar to insulinoma; as a result, many of them have undergone futile abdominal exploration and needless subtotal pancreatectomy in search of an insulinoma. The appropriate application and interpretation of available tests will preclude surgical exploration in them. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diabetic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factitious hypoglycemia among patients with diabetes is probably more common than the incidence noted in published series [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18951/abstract/17,18,20-22\">",
"     17,18,20-22",
"    </a>",
"    ]. Patients with diabetes are trained to manipulate doses of insulin for the purpose of achieving goal blood glucose values. When manipulation goes awry in the patient with factitious hypoglycemia, confirmation of the correct diagnosis can be very difficult.",
"   </p>",
"   <p>",
"    Patients with diabetes and factitious hypoglycemia usually appear to have brittle diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18951/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. They typically have repeated episodes of hypoglycemia despite a reduction in dose or even cessation of insulin therapy. Although insulinoma is an extraordinarily rare event in patients with diabetes, several patients with diabetes have undergone needless pancreatic exploration and resection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18951/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. When truly deprived of access to hypoglycemic agents, diabetic patients with factitious hypoglycemia become hyperglycemic.",
"   </p>",
"   <p>",
"    The identification of factitious disease as a cause of brittle diabetes requires three factors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18951/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A clinician who suspects the diagnosis",
"     </li>",
"     <li>",
"      Examination of the brittle diabetic state in a controlled environment",
"     </li>",
"     <li>",
"      Close patient follow-up to document manipulative behavior",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Careful studies of patients with brittle diabetes have shown that psychological problems play a major role in the swings in blood glucose [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18951/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18135?source=see_link\">",
"     \"The adult patient with brittle diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility of factitious hypoglycemia should be considered in every patient undergoing evaluation for a hypoglycemic disorder, especially when the hypoglycemia has a chaotic occurrence, ie, no relation at all to meals or fasting. All medications, including herbal preparations or other over-the-counter products, should be identified. The assistance of a pharmacist is desirable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;In persons for whom insulin or an oral insulin secretagogue has not been prescribed, the diagnosis of factitious hypoglycemia can usually be established by documenting the presence of hypoglycemia and by simultaneously measuring plasma insulin, C-peptide, proinsulin, and insulin secretagogues (sulfonylurea and meglitinides).",
"   </p>",
"   <p>",
"    Performance of a prolonged fast, which is primarily used to diagnose insulinoma, may be required in patients with factitious hypoglycemia should a spontaneous episode of hypoglycemia not be observed. Of course, the fast may be negative if the patient does not take the offending agent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24184?source=see_link&amp;anchor=H9#H9\">",
"     \"Hypoglycemia in adults without diabetes mellitus: Diagnostic approach\", section on '72-hour fast'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Interpretation of tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The interpretation of the test results is the same as when the tests are done during a spontaneous episode of hypoglycemia or during a 72-hour fast (",
"    <a class=\"graphic graphic_table graphicRef56314 \" href=\"UTD.htm?12/24/12685\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Insulin secretagogues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factitious hypoglycemia caused by sulfonylureas or meglitinides biochemically mimics the insulinoma response since these drugs stimulate insulin secretion. Patients with insulinoma and insulin secretagogue-induced hypoglycemia can have plasma insulin, C-peptide, and proinsulin values above or within the normal overnight fasting range. These ranges, however, are too high for the low plasma glucose concentration. In such cases, the detection of sulfonylureas or meglitinides in the plasma confirms the diagnosis of factitious hypoglycemia (",
"    <a class=\"graphic graphic_table graphicRef56314 \" href=\"UTD.htm?12/24/12685\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18951/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Exogenous insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In individuals with factitious hypoglycemia caused by exogenous administration of insulin, plasma insulin values are high (often above 100",
"    <span class=\"nowrap\">",
"     microU/mL),",
"    </span>",
"    whereas plasma C-peptide and proinsulin values are low (",
"    <a class=\"graphic graphic_table graphicRef56314 \" href=\"UTD.htm?12/24/12685\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There are, however, caveats to the interpretation of plasma insulin values, especially in patients who have autoimmune-mediated rather than factitious hypoglycemia. In autoimmune hypoglycemia, both the plasma insulin and C-peptide concentrations can be very high, with plasma insulin levels often well above 1000",
"    <span class=\"nowrap\">",
"     microU/mL",
"    </span>",
"    (6000",
"    <span class=\"nowrap\">",
"     pmol/L).",
"    </span>",
"    In addition to the difference in C-peptide concentration (high with autoimmune hypoglycemia and low with exogenous insulin), the presence of insulin antibodies in high titers can distinguish insulin autoimmune hypoglycemia from exogenous insulin administration (",
"    <a class=\"graphic graphic_table graphicRef56314 \" href=\"UTD.htm?12/24/12685\">",
"     table 1",
"    </a>",
"    ). The antibodies do not have to be measured during an episode of hypoglycemia. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Anti-insulin antibodies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Insulin measurements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some insulin assays detect only human insulin, whereas others detect both human insulin and synthetic insulin analogs (glargine, detemir, lispro, aspart) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18951/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. In addition, some assays have been developed to specifically measure insulin analogs (eg, lispro, aspart) or animal insulin (porcine, beef) without any crossreactivity with human insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18951/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. Assay specificity depends upon the selection of monoclonal antibody used for detection. Thus, it is important that the clinician knows which insulin assay is used and whether it measures human insulin, insulin analogs, or both.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Insulin secretagogue measurements",
"    </span>",
"    &nbsp;&mdash;&nbsp;In all hypoglycemic patients, except those with type 1 diabetes, plasma should be obtained during a hypoglycemic episode for the measurement of sulfonylureas and meglitinides (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/21/11606?source=see_link\">",
"     nateglinide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/25/4503?source=see_link\">",
"     repaglinide",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Many techniques for detection of first-generation sulfonylureas do not detect second-generation sulfonylureas or meglitinides. It is therefore important that the laboratory selected to make this measurement has a proven record with the assay and fastidious quality control procedures. The Department of Laboratory Medicine at the Mayo Clinic developed a liquid chromatography tandem mass spectrometry",
"    <span class=\"nowrap\">",
"     (LC/MS/MS)",
"    </span>",
"    method that has proven to be highly sensitive for the detection of these compounds (sulfonylureas and meglitinides). Similar type assays are available in other countries [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18951/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Capillary electrophoresis (CE) and high performance liquid chromatography (HPLC) assays are also available for detecting surreptitious abuse of sulfonylureas or meglitinides [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18951/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The misdiagnosis of insulinoma or insulin secretagogue factitious hypoglycemia is doubly injurious, depriving the patient of a potentially curative procedure (if the diagnosis of insulinoma is missed) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18951/abstract/40\">",
"     40",
"    </a>",
"    ] or leading to unnecessary surgery (if the diagnosis of insulin secretagogue use is missed).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     C-peptide measurements",
"    </span>",
"    &nbsp;&mdash;&nbsp;In hyperinsulinemic hypoglycemic patients, the distinction between an endogenous or exogenous source of insulin can be made by measuring plasma C-peptide in the sample used for the insulin determination (",
"    <a class=\"graphic graphic_table graphicRef56314 \" href=\"UTD.htm?12/24/12685\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18951/abstract/41\">",
"     41",
"    </a>",
"    ]. Isolated measurements of plasma glucose, insulin, and C-peptide are diagnostically useless. Interpretation of the value for any one of these substances is dependent upon the values of the other two. Insulin and C-peptide are secreted in an equimolar fashion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18951/abstract/42\">",
"     42",
"    </a>",
"    ]; as a result, the plasma concentrations of these two peptides parallel each other in patients with endogenous hyperinsulinemia.",
"   </p>",
"   <p>",
"    In contrast, the plasma concentrations of the two peptides are inversely related in patients with exogenous insulin factitious hypoglycemia: plasma insulin is high while C-peptide is appropriately suppressed, usually close to the lower limit of detection of the C-peptide assay. This observation applies to both nondiabetic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18951/abstract/15,18,43\">",
"     15,18,43",
"    </a>",
"    ] and to those with type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18951/abstract/17,18,22\">",
"     17,18,22",
"    </a>",
"    ]. Patients with type 1 diabetes are characteristically severely insulin deficient and have low or undetectable plasma concentrations of C-peptide. Although the C-peptide values in these patients cannot be further suppressed, confirmation that they are low during hypoglycemia eliminates any consideration of endogenous hyperinsulinism [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18951/abstract/21,44\">",
"     21,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Anti-insulin antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, the presence of anti-insulin antibodies in nondiabetic patients or patients with diabetes who had never been treated with insulin was taken as evidence favoring the surreptitious use of insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18951/abstract/18\">",
"     18",
"    </a>",
"    ]. However, the syndrome of autoimmune hypoglycemia in which insulin antibodies are spontaneously generated has complicated this interpretation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18951/abstract/28,45\">",
"     28,45",
"    </a>",
"    ]. Patients with this disorder have high plasma titers of insulin antibodies and a history of autoimmune disease or exposure to sulfhydryl-containing drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24184?source=see_link&amp;anchor=H18#H18\">",
"     \"Hypoglycemia in adults without diabetes mellitus: Diagnostic approach\", section on 'Determining the cause of hypoglycemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The detection of anti-insulin antibodies in insulin-treated patients is of no diagnostic utility, since they occur routinely. Human insulin generates antibodies in fewer patients and in lower titers (50 percent lower) than does purified porcine insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18951/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of anti-insulin antibodies can interfere with measurements of plasma insulin and C-peptide concentrations. As a result, plasma free insulin and C-peptide should be measured in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Long-term",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term treatment of factitious hypoglycemia involves changing abnormal behavioral patterns. Confrontation may be more effective when it is a collaborative intervention by the attending clinician and psychiatrist together. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7512?source=see_link&amp;anchor=H8#H8\">",
"     \"Factitious disorder and Munchausen syndrome\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Acute",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute management of factitious hypoglycemia is similar to the management of hypoglycemia during the treatment of diabetes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with symptomatic hypoglycemia should ingest carbohydrates. Fifteen to 20 grams of oral glucose is typically sufficient. Glucose may be ingested in the form of tablets, juice, milk, other snacks, or a meal.",
"     </li>",
"     <li>",
"      Treatment of severe hypoglycemia, when the patient is unconscious or unable to ingest carbohydrate, requires a subcutaneous or intramuscular injection of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"       glucagon",
"      </a>",
"      (0.5 to 1.0 mg).",
"     </li>",
"     <li>",
"      Patients brought to the hospital can be treated more quickly by giving 25 g of 50 percent glucose (dextrose) intravenously.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A subsequent glucose infusion (or food, if patient is able to eat) is often needed, depending upon the half-life of the drug causing the hypoglycemia.",
"   </p>",
"   <p>",
"    The treatment of hypoglycemia is reviewed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27641?source=see_link&amp;anchor=H34#H34\">",
"     \"Management of hypoglycemia during treatment of diabetes mellitus\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    in hypoglycemia associated with therapeutic use of sulfonylureas is unclear. As an example, in a trial of adult patients with sulfonylurea-induced hypoglycemia, subjects who were randomly assigned to receive octreotide (a single subcutaneous dose of 75 micrograms) in addition to one ampule of 50 percent dextrose (IV) had significantly higher mean glucose values during the first eight hours of therapy than those who received only IV dextrose [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18951/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13687?source=see_link\">",
"     \"Sulfonylurea agent poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/51/18226?source=see_link\">",
"       \"Patient information: Low blood sugar in people without diabetes (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factitious disease should be considered in every patient evaluated for a hypoglycemic disorder. In persons for whom insulin or an oral insulin secretagogue has not been prescribed, the diagnosis of factitious hypoglycemia can usually be established by assessing plasma glucose, insulin, C-peptide, proinsulin, and insulin secretagogues (sulfonylureas, meglitinides) during any episode of symptomatic hypoglycemia. Insulin antibodies should be measured once. A prolonged fast may be necessary should a spontaneous episode of hypoglycemia not be observed. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Laboratory tests'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24184?source=see_link&amp;anchor=H9#H9\">",
"     \"Hypoglycemia in adults without diabetes mellitus: Diagnostic approach\", section on '72-hour fast'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Interpretation of laboratory results",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonsuppressed plasma concentrations of insulin and C-peptide and the presence of sulfonylurea or meglitinide indicate factitious hypoglycemia caused by the oral insulin secretagogue (",
"      <a class=\"graphic graphic_table graphicRef56314 \" href=\"UTD.htm?12/24/12685\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Insulin secretagogues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonsuppressed plasma concentrations of insulin and C-peptide in the absence of sulfonylurea or meglitinides are suggestive of endogenous hyperinsulinemia (eg, insulinoma).",
"     </li>",
"     <li>",
"      Nonsuppressed plasma insulin and suppressed plasma C-peptide and proinsulin concentrations in the absence of measurable insulin secretagogues indicates factitious hypoglycemia due to insulin administration. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Exogenous insulin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Insulin autoimmune syndrome is characterized by high titers of insulin antibodies.",
"     </li>",
"     <li>",
"      In the presence of insulin antibodies, the measurement of plasma free insulin and free C-peptide may facilitate the determination of hyperinsulinemic hypoglycemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Patients with pre-existing diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In oral insulin secretagogue or insulin-treated diabetic patients, confirmation of factitious hypoglycemia can be very difficult. It requires an assessment under controlled conditions, where he or she can be closely monitored and observed, with all blood glucose testing, food, and insulin being administered by the staff. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Diabetic'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18135?source=see_link\">",
"     \"The adult patient with brittle diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute management of factitious hypoglycemia is similar to the management of hypoglycemia during the treatment of diabetes. The long-term treatment of factitious hypoglycemia involves changing abnormal behavioral patterns. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Treatment'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27641?source=see_link\">",
"     \"Management of hypoglycemia during treatment of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/1\">",
"      Hirshberg B, Skarulis MC, Pucino F, et al. Repaglinide-induced factitious hypoglycemia. J Clin Endocrinol Metab 2001; 86:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/2\">",
"      Marks V, Teale JD. Hypoglycemia: factitious and felonious. Endocrinol Metab Clin North Am 1999; 28:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/3\">",
"      Waickus CM, de Bustros A, Shakil A. Recognizing factitious hypoglycemia in the family practice setting. J Am Board Fam Pract 1999; 12:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/4\">",
"      DUNCAN GG, JENSON W, EBERLY RJ. Factitious hypoglycemia due to chlorpropamide. Report of a case, with clinical similarity to an islet cell tumor of the pancreas. JAMA 1961; 175:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/5\">",
"      Klonoff DC, Barrett BJ, Nolte MS, et al. Hypoglycemia following inadvertent and factitious sulfonylurea overdosages. Diabetes Care 1995; 18:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/6\">",
"      Aderka D, Pinkhas J. Inadvertently induced hypoglycemia. JAMA 1978; 240:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/7\">",
"      Hooper PL, Tello RJ, Burstein PJ, Abrams RS. Pseudoinsulinoma--the Diamox-Diabinese switch. N Engl J Med 1990; 323:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/8\">",
"      Ahlquist DA, Nelson RL, Callaway CW. Pseudoinsulinoma syndrome from inadvertent tolazamide ingestion. Ann Intern Med 1980; 93:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/9\">",
"      Kao SL, Chan CL, Tan B, et al. An unusual outbreak of hypoglycemia. N Engl J Med 2009; 360:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/10\">",
"      Giurgea I, Ulinski T, Touati G, et al. Factitious hyperinsulinism leading to pancreatectomy: severe forms of Munchausen syndrome by proxy. Pediatrics 2005; 116:e145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/11\">",
"      Given BD, Ostrega DM, Polonsky KS, et al. Hypoglycemia due to surreptitious injection of insulin. Identification of insulin species by high-performance liquid chromatography. Diabetes Care 1991; 14:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/12\">",
"      Roberge RJ, Martin TG, Delbridge TR. Intentional massive insulin overdose: recognition and management. Ann Emerg Med 1993; 22:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/13\">",
"      Kaminer Y, Robbins DR. Insulin misuse: a review of an overlooked psychiatric problem. Psychosomatics 1989; 30:19.",
"     </a>",
"    </li>",
"    <li>",
"     Service FJ, Moore GL. Factitial and autoimmune hypoglycemia. In: Hypoglycemic Disorders: Pathogenesis, Diagnosis, and Treatment, GK Hall Medical Publishers, 1983. p.129.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/15\">",
"      Murray BJ. Hypoglycemia secondary to factitious hyperinsulinism. Postgrad Med 1981; 69:237, 240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/16\">",
"      Roberts I, Cohen H, Reeves WG. Characterisation of antibodies to insulin to help diagnose factitious hypoglycaemia. Br Med J (Clin Res Ed) 1985; 290:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/17\">",
"      Ensberg M, Gossain VV, Rovner DR. Factitious hypoglycemia. Clues to identifying an elusive disorder. Postgrad Med 1986; 79:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/18\">",
"      Grunberger G, Weiner JL, Silverman R, et al. Factitious hypoglycemia due to surreptitious administration of insulin. Diagnosis, treatment, and long-term follow-up. Ann Intern Med 1988; 108:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/19\">",
"      Bhatnagar D. Diagnosis of factitious hypoglycaemia. Br J Hosp Med 1988; 40:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/20\">",
"      Dimitriadis G, Raptis S, Zoupas C, Schizas N. The validity of C-peptide measurement in the diagnosis of factitious hypoglycemia. Acta Diabetol Lat 1980; 17:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/21\">",
"      Miccoli R, Marchetti P, Giampietro O, et al. Factitious hypoglycemia in an insulin-dependent woman in the eighth week of gestation. Gynecol Obstet Invest 1986; 21:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/22\">",
"      Toth EL. Factitious hypoglycemia and the multiple personality disorder. Ann Intern Med 1990; 112:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/23\">",
"      Tattersall R, Gregory R, Selby C, et al. Course of brittle diabetes: 12 year follow up. BMJ 1991; 302:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/24\">",
"      Schade DS, Drumm DA, Eaton RP, Sterling WA. Factitious brittle diabetes mellitus. Am J Med 1985; 78:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/25\">",
"      Schade DS, Burge MR. Brittle diabetes: etiology and treatment. Adv Endocrinol Metab 1995; 6:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/26\">",
"      GITTLER RD, ZUCKER G, EISINGER R, STOLLER N. Amelioration of diabetes mellitus by an insulinoma. N Engl J Med 1958; 258:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/27\">",
"      Braithwaite SS, Eatherton JK, Ellos WJ, et al. The ethics of surreptitious diagnostics for factitious hypoglycemia. J Clin Ethics 1990; 1:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/28\">",
"      Klein RF, Seino S, Sanz N, et al. High performance liquid chromatography used to distinguish the autoimmune hypoglycemia syndrome from factitious hypoglycemia. J Clin Endocrinol Metab 1985; 61:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/29\">",
"      Perros P, Henderson AK, Carter DC, Toft AD. Lesson of the week. Are spontaneous hypoglycaemia, raised plasma insulin and C peptide concentrations, and abnormal pancreatic images enough to diagnose insulinoma? BMJ 1997; 314:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/30\">",
"      Neal JM, Han W. Insulin immunoassays in the detection of insulin analogues in factitious hypoglycemia. Endocr Pract 2008; 14:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/31\">",
"      Moriyama M, Hayashi N, Ohyabu C, et al. Performance evaluation and cross-reactivity from insulin analogs with the ARCHITECT insulin assay. Clin Chem 2006; 52:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/32\">",
"      Owen WE, Roberts WL. Cross-reactivity of three recombinant insulin analogs with five commercial insulin immunoassays. Clin Chem 2004; 50:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/33\">",
"      Bowsher RR, Lynch RA, Brown-Augsburger P, et al. Sensitive RIA for the specific determination of insulin lispro. Clin Chem 1999; 45:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/34\">",
"      Andersen L, J&oslash;rgensen PN, Jensen LB, Walsh D. A new insulin immunoassay specific for the rapid-acting insulin analog, insulin aspart, suitable for bioavailability, bioequivalence, and pharmacokinetic studies. Clin Biochem 2000; 33:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/35\">",
"      Walfish PG, Feig DS, Bauman WA. Factitious hyperinsulinemic hypoglycemia: confirmation of the diagnosis by a species-specific insulin radioimmunoassay. J Endocrinol Invest 1987; 10:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/36\">",
"      Hoizey G, Lamiable D, Trenque T, et al. Identification and quantification of 8 sulfonylureas with clinical toxicology interest by liquid chromatography-ion-trap tandem mass spectrometry and library searching. Clin Chem 2005; 51:1666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/37\">",
"      Wang M, Miksa IR. Multi-component plasma quantitation of anti-hyperglycemic pharmaceutical compounds using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 856:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/38\">",
"      Paroni R, Comuzzi B, Arcelloni C, et al. Comparison of capillary electrophoresis with HPLC for diagnosis of factitious hypoglycemia. Clin Chem 2000; 46:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/39\">",
"      Malli D, Gikas E, Vavagiannis A, et al. Determination of nateglinide in human plasma by high-performance liquid chromatography with pre-column derivatization using a coumarin-type fluorescent reagent. Anal Chim Acta 2007; 599:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/40\">",
"      Service FJ, McMahon MM, O'Brien PC, Ballard DJ. Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc 1991; 66:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/41\">",
"      Pf&uuml;tzner A, L&ouml;big M, Fortunato A, Forst T. Evaluation of a new fully automated one-step C-peptide chemiluminescence assay (LIAISON C-Peptid). Clin Lab 2003; 49:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/42\">",
"      Rubenstein AH, Block MB, Starr J, et al. Proinsulin and C-peptide in blood. Diabetes 1972; 21:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/43\">",
"      Biliotti GC, Vestrini G, Tonelli P, et al. Factitious hypoglycemia: an unusual clinical picture within Von M&uuml;nchausen's syndrome. Ital J Surg Sci 1983; 13:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/44\">",
"      Service FJ, Rubenstein A, Horwitz DL. C-peptide analysis in diagnosis of factitial hypoglycemia in an insulin-dependent diabetic. Mayo Clin Proc 1975; 50:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/45\">",
"      Seino S, Fu ZZ, Marks W, et al. Characterization of circulating insulin in insulin autoimmune syndrome. J Clin Endocrinol Metab 1986; 62:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/46\">",
"      Schernthaner G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 1993; 16 Suppl 3:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18951/abstract/47\">",
"      Fasano CJ, O'Malley G, Dominici P, et al. Comparison of octreotide and standard therapy versus standard therapy alone for the treatment of sulfonylurea-induced hypoglycemia. Ann Emerg Med 2008; 51:400.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1799 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-806F72AFFC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_32_18951=[""].join("\n");
var outline_f18_32_18951=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY OF FACTITIOUS HYPOGLYCEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Ingestion of an oral insulin secretagogue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Administration of insulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Nondiabetic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diabetic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Interpretation of tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Insulin secretagogues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Exogenous insulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Insulin measurements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Insulin secretagogue measurements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      C-peptide measurements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Anti-insulin antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Long-term",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Acute",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Interpretation of laboratory results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Patients with pre-existing diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1799\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1799|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/24/12685\" title=\"table 1\">",
"      Interpretation 72 hour fast",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7512?source=related_link\">",
"      Factitious disorder and Munchausen syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24184?source=related_link\">",
"      Hypoglycemia in adults without diabetes mellitus: Diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44664?source=related_link\">",
"      Hypoglycemia in adults: Clinical manifestations, definition, and causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12777?source=related_link\">",
"      Insulinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27641?source=related_link\">",
"      Management of hypoglycemia during treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36104?source=related_link\">",
"      Munchausen syndrome by proxy (medical child abuse)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/51/18226?source=related_link\">",
"      Patient information: Low blood sugar in people without diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13687?source=related_link\">",
"      Sulfonylurea agent poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18135?source=related_link\">",
"      The adult patient with brittle diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_32_18952="Treatment of hereditary hemochromatosis";
var content_f18_32_18952=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of hereditary hemochromatosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/32/18952/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/32/18952/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/32/18952/contributors\">",
"     Bruce R Bacon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/32/18952/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/32/18952/contributors\">",
"     William C Mentzer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/32/18952/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/32/18952/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/32/18952/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary hemochromatosis (HH), also called genetic hemochromatosis, is an inherited disorder in which mutations in the HFE gene or other genes (eg, hemojuvelin, hepcidin, ferroportin, ceruloplasmin) (",
"    <a class=\"graphic graphic_table graphicRef56329 \" href=\"UTD.htm?16/60/17356\">",
"     table 1",
"    </a>",
"    ) result in increased intestinal iron absorption. The treatment of this disorder will be discussed here [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], and is consistent with the 2011 Practice Guidelines for the diagnosis and management of HH from the American Association for the Study of Liver Diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The genetics, pathophysiology, clinical manifestations, diagnosis, and issues related to screening for HH are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=see_link\">",
"     \"Genetics of hereditary hemochromatosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=see_link\">",
"     \"Clinical manifestations of hereditary hemochromatosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=see_link\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12535?source=see_link\">",
"     \"Screening for hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATIONALE FOR TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Symptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of observations provide compelling reasons for early detection and therapy of symptomatic hereditary hemochromatosis (HH):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major causes of death in HH are decompensated cirrhosis, hepatocellular carcinoma, diabetes mellitus, and cardiomyopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/4-6\">",
"       4-6",
"      </a>",
"      ]. Survival was normal in HH patients in whom treatment was initiated before the development of cirrhosis or diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Despite prior reports to the contrary [",
"      <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/7,8\">",
"       7,8",
"      </a>",
"      ], data from the United Network for Organ Sharing, covering all liver transplants performed in the United States between 1997 and 2006, have indicated that the 217 recipients with a diagnosis of hemochromatosis had one-, three- and five-year survivals comparable to all other transplant recipients [",
"      <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Phlebotomy has a variety of benefits, including improvement in or resolution of varices [",
"      <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/10\">",
"       10",
"      </a>",
"      ], reduction in the degree of hepatic fibrosis if cirrhosis is absent [",
"      <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/11\">",
"       11",
"      </a>",
"      ], reversal of left ventricular dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/12-14\">",
"       12-14",
"      </a>",
"      ], and some reversal of secondary hypogonadism in men (",
"      <a class=\"graphic graphic_table graphicRef68740 \" href=\"UTD.htm?27/49/28444\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/15-17\">",
"       15-17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, not all patients improve and not all responders have complete recovery, particularly in patients with advanced disease. In a review of 30 patients with HH, cirrhosis, and varices, the varices improved or completely reversed in only 26 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/10\">",
"     10",
"    </a>",
"    ]. Similarly, hypogonadism typically improves in younger men but may be unlikely to improve in men over the age of 40 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/17\">",
"     17",
"    </a>",
"    ], and isolated reports suggest that some patients with severe cardiomyopathy do not improve with phlebotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/18\">",
"     18",
"    </a>",
"    ]. The arthritis does not usually improve. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2265?source=see_link&amp;anchor=H15#H15\">",
"     \"Rheumatic manifestations of hereditary hemochromatosis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These observations provide strong support for the early treatment of",
"    <strong>",
"     symptomatic",
"    </strong>",
"    HH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Asymptomatic patients",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Family screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the one available study of first degree relatives with HH uncovered by family screening, a substantial number had signs and symptoms related to HH that were not yet detected clinically [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/19\">",
"     19",
"    </a>",
"    ]. This suggests that screening of first degree relatives is likely to uncover a high percentage of affected individuals, many of whom do not yet have irreversible disease and would be expected to respond favorably to therapeutic phlebotomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12535?source=see_link&amp;anchor=H2#H2\">",
"     \"Screening for hereditary hemochromatosis\", section on 'Family screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Population screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients found to have homozygous HH during population screening studies are likely to be asymptomatic and have a normal lifespan even if they do not undergo phlebotomy. This was illustrated in a screening study of over 41,000 individuals from the Kaiser Permanente Clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/20\">",
"     20",
"    </a>",
"    ]. Among the 152 identified homozygotes for HH (0.4 percent), there was no increase in diabetes, arthropathy, arrhythmias, impotence, and skin pigmentation compared with those without HH and only one patient (0.7 percent of those with HH) had signs and symptoms suggestive of HH.",
"   </p>",
"   <p>",
"    Three relatively long-term studies provide confirmatory evidence of the low rate of symptomatic disease in asymptomatic individuals who are homozygous for HH:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of the 23 homozygotes detected in a Danish population study (0.25 percent of the 9174 screened subjects), none had clinically overt HH [",
"      <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/21\">",
"       21",
"      </a>",
"      ]. Although follow-up studies showed modest increases in transferrin saturation and ferritin during 25 years of follow-up, only one developed biochemical signs compatible with subclinical HH, and none required treatment.",
"     </li>",
"     <li>",
"      A retrospective study of 10 previously untreated subjects diagnosed with homozygous HH in 1998, who had clinical and laboratory information going back to 1981, indicated progressively increasing transferrin saturations during the 17-year period before diagnosis, with marked variation in serum ferritin levels [",
"      <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/22\">",
"       22",
"      </a>",
"      ]. The one patient in this group who developed cirrhosis also consumed more than six standard alcoholic drinks per day.",
"     </li>",
"     <li>",
"      HFE mutations were studied in a long-term prospective cohort involving 31,192 Australian subjects of Northern European descent aged 40 to 69 years who had iron studies 12 years apart [",
"      <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/23\">",
"       23",
"      </a>",
"      ]. The prevalence of HH-associated signs and symptoms at the time of follow-up was similar for the 102 previously undiagnosed C282Y homozygotes and the 291 HFE wild-types for those with normal serum ferritin at baseline (ie, &lt;300",
"      <span class=\"nowrap\">",
"       mcg/L",
"      </span>",
"      for men and postmenopausal women and &lt;200",
"      <span class=\"nowrap\">",
"       mcg/L",
"      </span>",
"      for premenopausal women) as well as for those with &ldquo;moderately elevated&rdquo; levels at baseline (ie, above normal but &lt;1000",
"      <span class=\"nowrap\">",
"       mcg/L).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It can be concluded from these studies that individuals with",
"    <strong>",
"     asymptomatic",
"    </strong>",
"    HH and ferritins &lt;1000",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    are at low risk for developing HH-related signs and symptoms in the future.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the authors of the Danish and Australian studies discussed above concluded that C282Y homozygotes identified through population screening, and not because of clinically overt HH, needed to be re-evaluated for manifestations of HH as infrequently as every 10 to 20 years, we prefer to follow such patients on a yearly basis. Our routine includes physical evaluation of the skin, heart, liver, joints, and endocrine organs, with yearly determination of the serum iron, ferritin, and transferrin saturation. Additional studies (eg, liver function testing, echocardiography) are done only when disease progression is evident.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PHLEBOTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The simplest, cheapest, and most effective way to remove accumulated iron in non-anemic patients with iron overload is via therapeutic phlebotomy. Each 500 mL of whole blood removed contains 200 to 250 mg of iron. In providing replacement for the hemoglobin lost along with the phlebotomized red cells, the body mobilizes an equal amount of iron from tissue stores, thereby reducing the degree of iron overload.",
"   </p>",
"   <p>",
"    Thus, for a patient with HH and estimated iron stores of 10 grams, one phlebotomy per week for 50 weeks should fully deplete the patient's accumulated iron stores.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients who have a clinical phenotype consistent with hemochromatosis (regardless of their genotype) will benefit from therapeutic phlebotomy. Possible exceptions include patients who have limited life expectancy due to other diseases,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    those who are anemic or otherwise do not tolerate phlebotomy (eg, ferroportin mutations, aceruloplasminemia, congestive failure with hemodynamic instability). Such patients may instead respond to iron chelation therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=see_link&amp;anchor=H16#H16\">",
"     \"Genetics of hereditary hemochromatosis\", section on 'Ferroportin mutations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=see_link&amp;anchor=H17#H17\">",
"     \"Genetics of hereditary hemochromatosis\", section on 'Aceruloplasminemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/49/25370?source=see_link\">",
"     \"Chelation therapy for iron overload states\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Phlebotomy should not be withheld based upon advanced age alone or in patients who are asymptomatic. Criteria for initiating therapeutic phlebotomy have been proposed by a panel of experts who formed the Hemochromatosis Management Working Group (",
"    <a class=\"graphic graphic_table graphicRef60083 \" href=\"UTD.htm?22/56/23435\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic phlebotomy can be performed in a physician's office, blood bank or other hospital facility, or at home by a well-trained phlebotomist. Patients should be encouraged to maintain hydration, and avoid vigorous exercise within 24 hours of phlebotomy. Symptoms of hypovolemia are more likely in patients who have a hemoglobin concentration less than 11",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    or a hematocrit less than 33 percent prior to treatment.",
"   </p>",
"   <p>",
"    The optimal regimen for phlebotomy in HH has not been established. However, it is preferable that patients be depleted of iron as quickly as possible [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/4,24\">",
"     4,24",
"    </a>",
"    ]. Removal of one unit of blood every one or two weeks usually suffices. A weekly phlebotomy removing 50 units of blood per year will remove approximately 10 to 12.5 g of iron. Male patients and those with large body mass may tolerate removal of 1.5 to 2 units per week, whereas women, the elderly, and those with a low body mass or cardiopulmonary disease may only tolerate removal of 0.5 units per week. The development of erythroid hyperplasia after a few weeks of phlebotomy often permits a more accelerated phlebotomy schedule.",
"   </p>",
"   <p>",
"    Patients with iron overload due to mutations of the iron export protein ferroportin may not tolerate the above rates of phlebotomy. However, with a less aggressive schedule, these patients can become iron depleted [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=see_link&amp;anchor=H16#H16\">",
"     \"Genetics of hereditary hemochromatosis\", section on 'Ferroportin mutations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The blood withdrawn from a patient with HH can be used for direct transfusion. FDA regulations require that the container should be labeled conspicuously to indicate that the donor had hemochromatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26106?source=see_link&amp;anchor=H6#H6\">",
"     \"Procedures used for blood donor screening: Protection of potential blood donors and recipients\", section on 'Use of blood withdrawn for therapeutic purposes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Endpoints",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although neither the hepatic iron index nor the serum ferritin concentration accurately predicts the phlebotomy requirement [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/27\">",
"     27",
"    </a>",
"    ], serum ferritin and the transferrin saturation can be used to monitor the response to phlebotomy. Two different methods are used by the authors, reflecting general preferences rather than evidence-based approaches.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One author (SLS) and many hematologists maintain weekly phlebotomies until iron deficiency hematopoiesis is induced, as evidenced by a hemoglobin concentration of 10 to 12",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      mean cell volume (MCV) in the low 80s [",
"      <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/28\">",
"       28",
"      </a>",
"      ], transferrin saturation of 10 to 20 percent, total iron binding capacity (TIBC) &gt;300",
"      <span class=\"nowrap\">",
"       microg/dL,",
"      </span>",
"      and a serum ferritin concentration within the low normal range (5 to 10",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      <span class=\"nowrap\">",
"       (microg/L)",
"      </span>",
"      in our laboratory). The resulting iron deficiency anemia does not need to be treated, as the increased absorption of food iron seen in HH will reverse the anemia in a few weeks following cessation of phlebotomies, without the need for iron supplements (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Maintenance'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      The second author (BRB) and many hepatologists recommend weekly phlebotomy until iron stores are normalized (defined as a serum ferritin concentration &lt;50",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      <span class=\"nowrap\">",
"       (microg/L)",
"      </span>",
"      and transferrin saturation &lt;50 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/1,29\">",
"       1,29",
"      </a>",
"      ]. It may be necessary to discontinue phlebotomy temporarily if the hemoglobin or hematocrit falls by more than 20 percent from prior values. The induction of iron deficiency is not viewed as necessary.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other recommendations have been proposed by consensus panels, including the Hemochromatosis Management Working Group and the American Association for the Study of Liver Diseases, which are similar to those of our second author, although with some variability in the frequency of phlebotomy, as well as the desired endpoints (",
"    <a class=\"graphic graphic_table graphicRef57962 \" href=\"UTD.htm?3/10/3243\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/3,24,30\">",
"     3,24,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the past, it was not uncommon to need 70 to 100 phlebotomies to remove the enormous iron stores in patients who presented with symptoms. However, with earlier diagnosis, 30 phlebotomies or fewer may be sufficient. In a series of 40 newly diagnosed patients who were seen between 1990 and 1995, for example, removal of a mean of 30 units of blood (approximately 7.5 g of iron) was required to normalize body iron stores (defined as a serum ferritin concentration below 50",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    and transferrin saturation below 50 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Maintenance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following example illustrates how rapidly some patients with HH can absorb iron after they have been iron depleted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A patient with HH was extensively phlebotomized until his serum ferritin concentration was less than 5",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      indicating that his iron stores were totally depleted. His hemoglobin concentration at that time was 11",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      with an MCV of 78. Three months later, the following results were noted: hemoglobin concentration 15",
"      <span class=\"nowrap\">",
"       g/dL;",
"      </span>",
"      MCV 91; serum ferritin concentration 40",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      and serum transferrin saturation 48 percent.",
"     </li>",
"     <li>",
"      The calculation of iron absorption in this patient is as follows. The increase in hemoglobin was 4",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      or 40",
"      <span class=\"nowrap\">",
"       g/L;",
"      </span>",
"      with a total blood volume of 5 liters, the total increase in hemoglobin was 200 g. There are 3.3 mg of iron in each gram of hemoglobin or 660 mg of iron in 200 g of hemoglobin. This quantity of iron (660 mg) must have been absorbed over 90 days, representing a net retention of 7.3 mg of iron per day, or 220",
"      <span class=\"nowrap\">",
"       mg/month,",
"      </span>",
"      the latter being the amount of iron present in one unit of whole blood.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Accordingly, a maintenance phlebotomy schedule should be continued in patients with HH following primary iron depletion to prevent reaccumulation of iron. A reasonable goal for maintenance is to keep the serum ferritin concentration between 50 and 100",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    which will enhance absorption of nonheme iron less than would occur if serum ferritin levels were kept at 20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    or less [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/1,32\">",
"     1,32",
"    </a>",
"    ]. For maintenance, most patients require a 500 mL phlebotomy every two to four months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7188250\">",
"    <span class=\"h2\">",
"     Erythrocytapheresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythrocytapheresis is a pheresis technique whereby red cells are removed in an isovolemic manner and the patient&rsquo;s plasma is also returned to the patient. When employed, with or without the use of erythropoietin, larger amounts of iron can be removed per session than by phlebotomy. This technique may result in the need for fewer treatment sessions and fewer side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/33-36\">",
"     33-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This benefit was shown in a small randomized study in 38 newly-diagnosed patients homozygous for C282Y, who were randomly assigned to treatment with standard phlebotomy or erythrocytapheresis. The mean number of treatment procedures needed to reach a serum ferritin target level of 50",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    was significantly lower in those assigned to receive erythrocytapheresis (9 versus 27; ratio 0.33; 95% CI 0.25-0.45) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/37\">",
"     37",
"    </a>",
"    ]. Adjustment for initial serum ferritin levels and body weight had only a minimal effect on this ratio (0.43; 95% CI 0.35-0.52). Cost analysis showed no significant difference in treatment costs between the two procedures; the costs resulting from productivity loss were significantly lower for the erythrocytapheresis group.",
"   </p>",
"   <p>",
"    The use of erythropoietin in this setting may not be reimbursed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIETARY LIMITATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Dietary iron intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are often concerned about the effect of specific foods on their iron balance. A normal balanced diet is usually sufficient. There is some evidence that higher levels of fresh fruit intake, excluding citrus fruits and juices, has a protective effect against high body iron status in subjects with or without HFE mutations, although this beneficial effect was noted only in men in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who are undergoing phlebotomy should not feel compelled to avoid moderate consumption of foods containing iron (such as red meat and organ meats). The excess iron absorption in hemochromatosis (0.5 to 1.0 mg of iron per day) is far exceeded by the removal of iron (200 to 250 mg per unit) by phlebotomy. However, dietary supplements containing iron should be avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Reducing iron absorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although some dietary substances can bind iron and inhibit its absorption (such as tannates, phytates, oxalates, calcium, and phosphates), supplementation or increased consumption of foods containing these substances is unnecessary in patients who are undergoing therapeutic phlebotomy.",
"   </p>",
"   <p>",
"    Of interest, absorption of dietary non-heme iron and phlebotomy requirements were noted to be significantly reduced in seven patients with classical HH who were treated with proton pump inhibitors for concomitant gastrointestinal disorders (eg, GERD) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Ethanol",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of reasons why patients with HH should avoid excessive alcohol intake:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ethanol can increase iron absorption, and some red wines contain relatively high concentrations of iron [",
"      <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Consumption of more than 60 g of alcohol per day (the amount contained in approximately four glasses of wine or beer) was associated with a ninefold increase in the likelihood of developing cirrhosis in a cohort of 224 C282Y homozygous patients with documented iron overload [",
"      <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/41\">",
"       41",
"      </a>",
"      ]. The risk was increased with alcohol consumption as little as 40 g per day.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients in the high-alcohol group also had a higher incidence of hepatocellular carcinoma, and developed cirrhosis at a lower mean hepatic iron concentration and at a younger age than those with lesser alcohol consumption. Accordingly, patients with HH should not abuse alcohol, but occasional social drinking is permissible in those without significant liver disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Ascorbic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ascorbic acid (vitamin C) may enhance the liberation of free iron and the generation of reactive oxygen species. Ingestion of large quantities of vitamin C has been rarely associated with fatal cardiac arrhythmias in patients with iron overload, presumably due to oxidative injury [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/42\">",
"     42",
"    </a>",
"    ]. Thus, it may be reasonable to advise patients to avoid vitamin C supplements [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/43\">",
"     43",
"    </a>",
"    ], but there is no reason to discourage the consumption of fresh fruits or vegetables containing vitamin C [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/24,38\">",
"     24,38",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Dietary iron intake'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Uncooked seafood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HH are at risk for certain infections with bacteria which thrive on the increased plasma iron concentrations. Accordingly, it has been recommended that patients with HH avoid consumption of uncooked seafood [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical manifestations of hereditary hemochromatosis\", section on 'Susceptibility to specific infections'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     IRON CHELATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chelation therapy for HH (eg, with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"     deferasirox",
"    </a>",
"    ) can lead to clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    laboratory improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/14,44,45\">",
"     14,44,45",
"    </a>",
"    ]. However, it is almost never necessary because of the ease and efficacy of phlebotomy compared with chelation therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/49/25370?source=see_link\">",
"     \"Chelation therapy for iron overload states\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of HH on overall mortality is unclear. In the available studies, the mortality risk for patients with homozygous HH has varied from that of the unaffected population to as high as 2.45 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/46\">",
"     46",
"    </a>",
"    ]. This issue was addressed in depth in a Swedish population-based cohort study of 3832 patients with HH and their 14,496 first-degree relatives, as well as 38,969 population controls and their 143,349 first-degree relatives. Results of this study included the following [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/46\">",
"     46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with HH identified on the basis of hospitalization had a significantly increased risk for death (RR 2.45; 95% CI 2.27-2.64). Those identified by other means (eg, screening of family members, routine outpatient testing) had a mortality risk for death that was lower than that of those identified in the hospital but marginally higher than that of unaffected controls (RR 1.15; 95 % CI 1.00-1.33).",
"     </li>",
"     <li>",
"      Patients with HH who also had a family history of HH did not have an increased mortality risk compared with other groups (RR 1.05; 95% CI 0.67-1.62).",
"     </li>",
"     <li>",
"      First-degree relatives of those diagnosed with HH had only a marginally increased mortality risk (RR 1.05; 95% CI 1.01-1.10), which was similar to that of the spouses of patients with HH (RR 1.09; 95% CI 0.86-1.38).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the presence or absence of cirrhosis appears to be a major determinant of prognosis in HH [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/4,5,47,48\">",
"     4,5,47,48",
"    </a>",
"    ]. In one study of 251 patients, for example, survival was shortened in patients with cirrhosis and diabetes but was normal in those without cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18952/abstract/5\">",
"     5",
"    </a>",
"    ]. Analysis of the causes of death in 69 patients revealed the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hepatocellular carcinoma (HCC) &mdash; 19 patients, 119 times more common than in a control population",
"     </li>",
"     <li>",
"      Cirrhosis &mdash; 14 patients, 10 times more common",
"     </li>",
"     <li>",
"      Cardiomyopathy &mdash; 5 patients, 306 times more common",
"     </li>",
"     <li>",
"      Diabetes mellitus &mdash; 4 patients, 14 times more common",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Liver cancers were associated with cirrhosis and the amount of mobilizable iron, but not with the presence of hepatitis B or C markers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40179?source=see_link\">",
"       \"Patient information: Hemochromatosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/41/2709?source=see_link\">",
"       \"Patient information: Hemochromatosis (hereditary iron overload) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Indications for treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of patients found to have homozygous hereditary hemochromatosis (HH) during population or family screening studies are likely to be asymptomatic and without evidence for significant end-organ damage.",
"     </li>",
"     <li>",
"      Subjects with asymptomatic HH and ferritins &lt;1000 are at low risk for developing HH-related signs and symptoms in the future. Such patients need only yearly examination along with determination of the serum iron, ferritin, and transferrin saturation. Additional studies are done only when disease progression is evident. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Asymptomatic patients'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=see_link\">",
"       \"Clinical manifestations of hereditary hemochromatosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Symptomatic patients",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      those with end-organ damage (ie, liver, endocrine organs, heart) require treatment to remove excess iron stores. Such treatment may improve diabetes, hepatic fibrosis, varices, cardiac function, secondary hypogonadism, and prevent the development of hepatocellular carcinoma (",
"      <a class=\"graphic graphic_table graphicRef68740 \" href=\"UTD.htm?27/49/28444\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Symptomatic patients'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Initial treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As initial treatment in symptomatic patients with HH, those with end-organ damage, and those with progressively increasing levels of serum ferritin (",
"      <a class=\"graphic graphic_table graphicRef60083 \" href=\"UTD.htm?22/56/23435\">",
"       table 3",
"      </a>",
"      ), we recommend the immediate institution of a program of weekly or biweekly phlebotomy over iron chelation therapy or no therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Schedule'",
"      </a>",
"      above.) Chelation therapy to remove accumulated iron is indicated only if the patient is unable to tolerate phlebotomy therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=see_link&amp;anchor=H16#H16\">",
"       \"Genetics of hereditary hemochromatosis\", section on 'Ferroportin mutations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=see_link&amp;anchor=H17#H17\">",
"       \"Genetics of hereditary hemochromatosis\", section on 'Aceruloplasminemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Phlebotomy should continue until the patient shows evidence for a reduction in iron stores, as evidenced by a ferritin concentration in the range of 50 to 100",
"      <span class=\"nowrap\">",
"       ng/mL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Endpoints'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is reasonable to limit the intake of ethanol, avoid taking iron or vitamin C supplements, and avoid ingestion of uncooked seafood. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Dietary limitations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Screening of first degree family members of the affected patient is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12535?source=see_link&amp;anchor=H2#H2\">",
"       \"Screening for hereditary hemochromatosis\", section on 'Family screening'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with HH and cirrhosis are at risk for, and need to be screened for, hepatocellular carcinoma on a continuing, periodic basis. Screening guidelines are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28778?source=see_link\">",
"       \"Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Maintenance therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that a maintenance phlebotomy schedule be employed following primary iron depletion to prevent reaccumulation of iron (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Maintenance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A reasonable goal is to keep the serum ferritin concentration in the range of 50 to 100",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      <span class=\"nowrap\">",
"       (mcg/L),",
"      </span>",
"      which is achieved in most patients via a 500 mL phlebotomy every two to four months (",
"      <a class=\"graphic graphic_table graphicRef57962 \" href=\"UTD.htm?3/10/3243\">",
"       table 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/1\">",
"      Adams PC, Barton JC. How I treat hemochromatosis. Blood 2010; 116:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/2\">",
"      van Bokhoven MA, van Deursen TB, Swinkels DW. Diagnosis and management of hereditary hemochromatosis. Br Med J 2011; 342:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/3\">",
"      Bacon BR, Adams PC, Kowdley KV, et al. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/4\">",
"      Niederau C, Fischer R, Sonnenberg A, et al. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985; 313:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/5\">",
"      Niederau C, Fischer R, P&uuml;rschel A, et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996; 110:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/6\">",
"      Fargion S, Fracanzani AL, Piperno A, et al. Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis. Hepatology 1994; 20:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/7\">",
"      Brandhagen DJ, Alvarez W, Therneau TM, et al. Iron overload in cirrhosis-HFE genotypes and outcome after liver transplantation. Hepatology 2000; 31:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/8\">",
"      Kowdley KV, Brandhagen DJ, Gish RG, et al. Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry. Gastroenterology 2005; 129:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/9\">",
"      Yu L, Ioannou GN. Survival of liver transplant recipients with hemochromatosis in the United States. Gastroenterology 2007; 133:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/10\">",
"      Fracanzani AL, Fargion S, Romano R, et al. Portal hypertension and iron depletion in patients with genetic hemochromatosis. Hepatology 1995; 22:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/11\">",
"      Powell LW, Dixon JL, Ramm GA, et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med 2006; 166:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/12\">",
"      Rivers J, Garrahy P, Robinson W, Murphy A. Reversible cardiac dysfunction in hemochromatosis. Am Heart J 1987; 113:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/13\">",
"      Easley RM Jr, Schreiner BF Jr, Yu PN. Reversible cardiomyopathy associated with hemochromatosis. N Engl J Med 1972; 287:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/14\">",
"      Rahko PS, Salerni R, Uretsky BF. Successful reversal by chelation therapy of congestive cardiomyopathy due to iron overload. J Am Coll Cardiol 1986; 8:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/15\">",
"      Kelly TM, Edwards CQ, Meikle AW, Kushner JP. Hypogonadism in hemochromatosis: reversal with iron depletion. Ann Intern Med 1984; 101:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/16\">",
"      Siemons LJ, Mahler CH. Hypogonadotropic hypogonadism in hemochromatosis: recovery of reproductive function after iron depletion. J Clin Endocrinol Metab 1987; 65:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/17\">",
"      Cundy T, Butler J, Bomford A, Williams R. Reversibility of hypogonadotrophic hypogonadism associated with genetic haemochromatosis. Clin Endocrinol (Oxf) 1993; 38:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/18\">",
"      Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 31-1994. A 25-year-old man with the recent onset of diabetes mellitus and congestive heart failure. N Engl J Med 1994; 331:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/19\">",
"      Bulaj ZJ, Ajioka RS, Phillips JD, et al. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med 2000; 343:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/20\">",
"      Beutler E, Felitti VJ, Koziol JA, et al. Penetrance of 845G--&gt; A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002; 359:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/21\">",
"      Andersen RV, Tybjaerg-Hansen A, Appleyard M, et al. Hemochromatosis mutations in the general population: iron overload progression rate. Blood 2004; 103:2914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/22\">",
"      Olynyk JK, Hagan SE, Cullen DJ, et al. Evolution of untreated hereditary hemochromatosis in the Busselton population: a 17-year study. Mayo Clin Proc 2004; 79:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/23\">",
"      Allen KJ, Bertalli NA, Osborne NJ, et al. HFE Cys282Tyr homozygotes with serum ferritin concentrations below 1000 microg/L are at low risk of hemochromatosis. Hepatology 2010; 52:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/24\">",
"      Barton JC, McDonnell SM, Adams PC, et al. Management of hemochromatosis. Hemochromatosis Management Working Group. Ann Intern Med 1998; 129:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/25\">",
"      Pietrangelo A. Non-HFE hemochromatosis. Hepatology 2004; 39:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/26\">",
"      Tan L, Khan MK, Hawk JC 3rd. Use of blood therapeutically drawn from hemochromatosis patients. Council on Scientific Affairs, American Medical Association. Transfusion 1999; 39:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/27\">",
"      Olynyk JK, Luxon BA, Britton RS, Bacon BR. Hepatic iron concentration in hereditary hemochromatosis does not saturate or accurately predict phlebotomy requirements. Am J Gastroenterol 1998; 93:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/28\">",
"      Bolan CD, Conry-Cantilena C, Mason G, et al. MCV as a guide to phlebotomy therapy for hemochromatosis. Transfusion 2001; 41:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/29\">",
"      Bacon BR, Powell LW, Adams PC, et al. Molecular medicine and hemochromatosis: at the crossroads. Gastroenterology 1999; 116:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/30\">",
"      Tavill AS, American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastroenterological Association. Diagnosis and management of hemochromatosis. Hepatology 2001; 33:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/31\">",
"      Bacon BR, Sadiq SA. Hereditary hemochromatosis: presentation and diagnosis in the 1990s. Am J Gastroenterol 1997; 92:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/32\">",
"      Lynch SR, Skikne BS, Cook JD. Food iron absorption in idiopathic hemochromatosis. Blood 1989; 74:2187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/33\">",
"      Kohan A, Niborski R, Daruich J, et al. Erythrocytapheresis with recombinant human erythropoietin in hereditary hemochromatosis therapy: a new alternative. Vox Sang 2000; 79:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/34\">",
"      Muncunill J, Vaquer P, Galm&eacute;s A, et al. In hereditary hemochromatosis, red cell apheresis removes excess iron twice as fast as manual whole blood phlebotomy. J Clin Apher 2002; 17:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/35\">",
"      Mariani R, Pelucchi S, Perseghin P, et al. Erythrocytapheresis plus erythropoietin: an alternative therapy for selected patients with hemochromatosis and severe organ damage. Haematologica 2005; 90:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/36\">",
"      Rombout-Sestrienkova E, van Noord PA, van Deursen CT, et al. Therapeutic erythrocytapheresis versus phlebotomy in the initial treatment of hereditary hemochromatosis - A pilot study. Transfus Apher Sci 2007; 36:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/37\">",
"      Rombout-Sestrienkova E, Nieman FH, Essers BA, et al. Erythrocytapheresis versus phlebotomy in the initial treatment of HFE hemochromatosis patients: results from a randomized trial. Transfusion 2012; 52:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/38\">",
"      Milward EA, Baines SK, Knuiman MW, et al. Noncitrus fruits as novel dietary environmental modifiers of iron stores in people with or without HFE gene mutations. Mayo Clin Proc 2008; 83:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/39\">",
"      Hutchinson C, Geissler CA, Powell JJ, Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut 2007; 56:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/40\">",
"      Celada A, Rudolf H, Donath A. Effect of experimental chronic alcohol ingestion and folic acid deficiency on iron absorption. Blood 1979; 54:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/41\">",
"      Fletcher LM, Dixon JL, Purdie DM, et al. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology 2002; 122:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/42\">",
"      McLaran CJ, Bett JH, Nye JA, Halliday JW. Congestive cardiomyopathy and haemochromatosis--rapid progression possibly accelerated by excessive ingestion of ascorbic acid. Aust N Z J Med 1982; 12:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/43\">",
"      Herbert V. Hemochromatosis and vitamin C. Ann Intern Med 1999; 131:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/44\">",
"      Nielsen P, Fischer R, Buggisch P, Janka-Schaub G. Effective treatment of hereditary haemochromatosis with desferrioxamine in selected cases. Br J Haematol 2003; 123:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/45\">",
"      Phatak P, Brissot P, Wurster M, et al. A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Hepatology 2010; 52:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/46\">",
"      Elmberg M, Hultcrantz R, Ebrahim F, et al. Increased mortality risk in patients with phenotypic hereditary hemochromatosis but not in their first-degree relatives. Gastroenterology 2009; 137:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/47\">",
"      Milman N, Pedersen P, &aacute; Steig T, et al. Clinically overt hereditary hemochromatosis in Denmark 1948-1985: epidemiology, factors of significance for long-term survival, and causes of death in 179 patients. Ann Hematol 2001; 80:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18952/abstract/48\">",
"      Crooks CJ, West J, Solaymani-Dodaran M, Card TR. The epidemiology of haemochromatosis: a population-based study. Aliment Pharmacol Ther 2009; 29:183.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7136 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-189.2.19.178-DF24B1B659-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_32_18952=[""].join("\n");
var outline_f18_32_18952=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATIONALE FOR TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Symptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Asymptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Family screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Population screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PHLEBOTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Patient selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Schedule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Endpoints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Maintenance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7188250\">",
"      Erythrocytapheresis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIETARY LIMITATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Dietary iron intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Reducing iron absorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Ethanol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Ascorbic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Uncooked seafood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      IRON CHELATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Indications for treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Initial treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7136\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7136|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/60/17356\" title=\"table 1\">",
"      Variants hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/49/28444\" title=\"table 2\">",
"      Results of phlebotomy in HH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/56/23435\" title=\"table 3\">",
"      Criteria for phlebotomy in HH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/10/3243\" title=\"table 4\">",
"      AASLD Rx guidelines HH",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/49/25370?source=related_link\">",
"      Chelation therapy for iron overload states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=related_link\">",
"      Clinical manifestations of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=related_link\">",
"      Genetics of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=related_link\">",
"      Pathophysiology and diagnosis of iron overload syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40179?source=related_link\">",
"      Patient information: Hemochromatosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/41/2709?source=related_link\">",
"      Patient information: Hemochromatosis (hereditary iron overload) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28778?source=related_link\">",
"      Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26106?source=related_link\">",
"      Procedures used for blood donor screening: Protection of potential blood donors and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2265?source=related_link\">",
"      Rheumatic manifestations of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12535?source=related_link\">",
"      Screening for hereditary hemochromatosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_32_18953="Kikuchis disease lymph node histopathology 2";
var content_f18_32_18953=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50349&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50349&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    CD68-stained lymph node from a patient with Kikuchi's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CD68-stained (monocyte/macrophage marker) lymph node at 200x magnification, showing the interface between residual normal lymph node and necrotic areas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Anthony Landgren.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_32_18953=[""].join("\n");
var outline_f18_32_18953=null;
var title_f18_32_18954="Overview of the systemic and nonarticular manifestations of rheumatoid arthritis";
var content_f18_32_18954=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the systemic and nonarticular manifestations of rheumatoid arthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/32/18954/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/32/18954/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/32/18954/contributors\">",
"     Eric L Matteson, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/32/18954/contributors\">",
"     Carl Turesson, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/32/18954/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/32/18954/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/32/18954/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/32/18954/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/32/18954/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although rheumatoid arthritis (RA) develops its central pathology within the synovium of diarthrodial joints, many nonarticular organs become involved, particularly in patients with severe joint disease. Despite the differences between the normal form and function of joints and, for example, the bone marrow, it is becoming clearer that the same cytokines that drive synovial pathology are also responsible for generating pathology in extraarticular tissues. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41210?source=see_link\">",
"     \"Pathogenesis of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Involvement of the musculoskeletal system other than joints (eg, bone and muscle) and of organs not considered part of the musculoskeletal system (eg, skin, eye, lung, heart, kidney, blood vessels, salivary glands, central and peripheral nervous systems, and bone marrow) occurs in about 40 percent of patients with RA over a lifetime of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These manifestations are reviewed here. Articular manifestations are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link\">",
"     \"Clinical features of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risk factors for systemic, extraarticular disease include the presence of rheumatoid factor (RF) and smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients with severe extraarticular RA often have high levels of RF at presentation of systemic manifestations and are more likely to have circulating antibodies against citrullinated proteins than are patients with RA but without extraarticular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Extraarticular involvement in rheumatoid arthritis is a marker of disease severity and is associated with increased overall morbidity and premature mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Successful management of systemic manifestations of RA is predicated upon control of the underlying joint disease and often includes glucocorticoid and immunosuppressive treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OSTEOPENIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteopenia in RA may be generalized, resulting from immobility, the inflammatory process, and treatment effects with glucocorticoids; it also includes periarticular demineralization typical of RA. It is due to the combined actions of prostaglandins and cytokines in association with normal amounts of parathyroid hormone. In the absence of antiresorptive therapy, all patients with RA can be expected to lose bone mineral [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/8\">",
"     8",
"    </a>",
"    ]. The decrease in bone secondary to the disease itself is separate from glucocorticoid-induced osteopenia; in some patients, however, the disease and glucocorticoid treatment are additive, producing substantial morbidity. These individuals are those who are particularly prone to loss of height, to symptomatic vertebral compression fractures, and to stress fractures of metatarsals or long bones in the leg. Patients who develop fractures often are immobilized for significant periods, and this deficiency of normal weightbearing amplifies bone loss by diminishing new bone formation while bone resorption continues at an accelerated pace.",
"   </p>",
"   <p>",
"    Periodontal bone loss may be associated with joint destruction at the wrist, and both were associated with the possession of the &ldquo;shared epitope&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/9\">",
"     9",
"    </a>",
"    ]. The presence of a lymphocytic infiltration of the salivary glands and the sicca syndrome were also associated with periodontal bone resorption in this study [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H38\">",
"     'Sj&ouml;gren's syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Bone formation is decreased in rheumatoid patients not treated with glucocorticoids, compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/10\">",
"     10",
"    </a>",
"    ]. An inverse association has been found between measurements of acute phase reactants and bone mineral density [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/11\">",
"     11",
"    </a>",
"    ], although, in this same cohort, no correlation could be found between bone mineral density and joint counts, swollen joints, or degree of general health.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoporosis of the hip or lumbar spine is common in adults with RA. This was illustrated in one study of 287 Norwegian patients among whom the prevalence of osteoporosis, as indicated by a bone mineral density of more than 2.5 standard deviations below the average for healthy young people at one or both sites, was 22 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are conflicting data on the frequency of glucocorticoid-associated osteopenia in rheumatoid patients taking low-dose (&lt;7.5",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . This issue and the mechanism of glucocorticoid-induced osteoporosis are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis\", section on 'Effect of low-dose glucocorticoid therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All else being equal, it is likely that net bone loss in a patient with RA who is taking low-dose daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    would exceed that in a patient not treated with glucocorticoids. However, it is possible that, in those patients who gain greater mobility and exercise tolerance, with the use of 5 to 7.5 mg of prednisone each day, the increase in bone loss from the therapy would be offset by an increase in new bone formation associated with an increase in muscle contraction and weightbearing [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/13\">",
"     13",
"    </a>",
"    ]. In a multivariable analysis of several risk factors for vertebral compression fracture in 925 women with RA, a one point increase in disability (as measured by the health assessment questionnaire) was associated with more fracture risk than a 1 gram cumulative dose of prednisone [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, there may be factors other than the disease process itself and glucocorticoid therapy that are associated with an increased risk of osteoporosis. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Postmenopausal state",
"     </li>",
"     <li>",
"      A previous diagnosis of osteoporosis",
"     </li>",
"     <li>",
"      Disability",
"     </li>",
"     <li>",
"      Increased age",
"     </li>",
"     <li>",
"      Inadequate physical activity",
"     </li>",
"     <li>",
"      Female sex",
"     </li>",
"     <li>",
"      Family history of osteoporosis",
"     </li>",
"     <li>",
"      Disease duration",
"     </li>",
"     <li>",
"      Impaired grip strength",
"     </li>",
"     <li>",
"      Low body mass",
"     </li>",
"     <li>",
"      Fair complexion",
"     </li>",
"     <li>",
"      Cigarette smoking",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although most studies of osteopenia in patients with RA have included a preponderance of women, men with the disorder also appear to have lower bone mass. In one study of 94 males with RA compared with population controls, there was a twofold increase in osteopenia among patients (bone mineral density [BMD] decreased by more than one standard deviation [SD]) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/15\">",
"     15",
"    </a>",
"    ]. Multiple regression analysis found advancing age and lower body weight to be associated with lower BMD at the femoral neck and total hip. However, disease-related factors, including concurrent glucocorticoid use, rheumatoid factor status, and self-reported disability, were not associated with osteopenia in the hip or spine.",
"   </p>",
"   <p>",
"    There is a high incidence of stress fracture of long bones in patients with RA, particularly in those treated with glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/16\">",
"     16",
"    </a>",
"    ]. Synovitis and glucocorticoid use are both risk factors for thinning of cortical bone [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/17\">",
"     17",
"    </a>",
"    ]. The fibula is the most common fracture site and, in older patients, often manifests as acute and debilitating pain in the lateral leg with no history of trauma. Other fractures can be facilitated by geodes, the subchondral cysts that develop when high intraarticular pressures force synovial fluid through breaks in the subchondral plate in patients who have particularly aggressive, proliferative synovitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/18\">",
"     18",
"    </a>",
"    ]. Vertebral compression deformities are also more common among those with RA than among age- and gender-matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/19\">",
"     19",
"    </a>",
"    ]. The higher prevalence is not fully explained by their lower BMD or by the use of glucocorticoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;It should be assumed that every patient with RA is at risk for osteoporosis. Those patients with added risk factors outlined above should be considered for baseline determinations of bone mineral density before the disease becomes well-entrenched and before glucocorticoid therapy is started. Dual energy x-ray absorptiometry, if available, is a precise and popular method for measuring bone density; quantitative computerized tomography is another option. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11128?source=see_link\">",
"     \"Diagnosis and evaluation of osteoporosis in postmenopausal women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The generalized and periarticular osteopenia that affects all patients with RA should lead to a low threshold for therapy to prevent bone loss. Interventions that are used to prevent or minimize RA and glucocorticoid-induced bone loss are presented elsewhere. Rheumatologists and primary care clinicians should have a low threshold for initiating bisphosphonate therapy in patients, particularly postmenopausal women, with RA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13591?source=see_link&amp;anchor=H9#H9\">",
"     \"Nonpharmacologic and preventive therapies of rheumatoid arthritis\", section on 'Bone protection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MUSCLE WEAKNESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle weakness is a common symptom in rheumatoid arthritis. It may have several, often additive, causes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Synovial inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synovial inflammation is usually associated with diminished motion of joints, which rapidly results in atrophy of muscle serving these joints. This effect is most obvious in the knee, in which synovitis quickly leads to quadriceps weakness. This weakness results in greater mechanical stress on the affected joints. As an example, when quadriceps weaken, more force is applied directly through the patella than when quadriceps strength is normal. Exercise can help prevent muscle weakness or can help restore muscle strength when due to synovitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13591?source=see_link&amp;anchor=H5#H5\">",
"     \"Nonpharmacologic and preventive therapies of rheumatoid arthritis\", section on 'Exercise'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Myositis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In autopsy series, focal accumulation of lymphocytes and plasma cells contiguous with foci of muscle necrosis are found in almost all patients with RA. These lesions have been called nodular myositis. They are particularly common in a small but interesting subset of patients who have mild synovitis and a disproportionately elevated erythrocyte sedimentation rate [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/20\">",
"     20",
"    </a>",
"    ]. Some foci of muscle lymphocytes have been shown to synthesize immunoglobulin M (IgM) rheumatoid factor [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rarely, a patient with RA develops a true polymyositis, with elevated levels of serum creatine kinase and with typical findings on electromyography and muscle biopsy. These patients should be managed as are those with polymyositis, by using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    in moderately high doses (60 to 80",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and by having a plan of moving quickly to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (25 mg",
"    <span class=\"nowrap\">",
"     intramuscular/week)",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (up to 2.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=see_link\">",
"     \"Initial treatment of dermatomyositis and polymyositis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most rheumatoid patients have generalized atrophy of type II fibers. This is probably due to disuse as described above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with RA may occasionally develop vasculitis. Risk factors include high titers of rheumatoid factor and active extraarticular disease elsewhere, such as nodulosis or scleritis. Involvement of skeletal muscle vessels can cause acute pain in muscle bundles associated with an acute flare of disease, while a vasculitic neuropathy can cause muscle weakness and a mononeuritis multiplex. With the use of aggressive and effective disease-modifying antirheumatic drug (DMARD) therapies for RA, this manifestation has become less common, occurring in less than 1 percent of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20697?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rheumatoid vasculitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Drug-induced myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superimposed on active RA, with or without muscle involvement, a drug-induced myopathy can gradually weaken a patient and can confuse the clinician who may assume that there is an inflammatory cause for the weakness. Glucocorticoids, antimalarial drugs, and statin drugs are among the drugs that can cause myopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is wide variation in the glucocorticoid dose and duration of treatment prior to the onset of muscle weakness. Some patients become weak after a low dose of glucocorticoids for a few weeks, while others never develop myopathy despite receiving large doses for months or years. Despite this variability, there is a general dose relationship for systemic glucocorticoid therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23173?source=see_link\">",
"     \"Glucocorticoid-induced myopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucocorticoid myopathy is unusual in patients treated with less than 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or its equivalent.",
"     </li>",
"     <li>",
"      The higher the dose of glucocorticoid, the greater is the likelihood of developing myopathy, and the more rapid is the onset of weakness. Daily doses in excess of 40 to 60",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      can induce clinically important weakness within two weeks and almost always result in some degree of muscle weakness when continued for more than one month.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other features of glucocorticoid excess such as moon facies, diabetes, mood alteration, skin fragility, and osteoporosis are often, but not always, present in patients with myopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Glucocorticoid-induced myopathy is a diagnosis of exclusion, being based upon the history and timing of glucocorticoid exposure and upon the absence of other causes of myopathy. The diagnosis should be strongly suspected if weakness develops at a time when the other signs of RA have become quiescent, and it is generally established by demonstrating improved strength within",
"    <strong>",
"     three to four weeks",
"    </strong>",
"    after appropriate dose reduction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Antimalarial drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimalarial drugs used to treat RA (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    ) rarely cause muscle weakness as a symptom of drug-induced myopathy. Antimalarial drug-induced myopathy is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=see_link&amp;anchor=H10#H10\">",
"     \"Drug-induced myopathies\", section on 'Antimalarial drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Lipid-lowering drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recognition of the increased incidence of cardiovascular disease in patients with RA and of the increased prevalence of traditional risk factors for coronary artery and other atherosclerotic disease has lead to more vigorous use of lipid-lowering agents, especially statins, in many adults with RA. Statins and other lipid-lowering drugs may cause muscle injury, typically with muscle pain. Thus, treatment with a statin or, rarely, with other lipid-lowering drugs should be considered as a cause of myalgia or weakness in a patient with RA who is being treated for dyslipidemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=see_link\">",
"     \"Statin myopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SKIN DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common of the cutaneous manifestations of RA is the rheumatoid nodule [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/21\">",
"     21",
"    </a>",
"    ]. Other cutaneous manifestations may arise when rheumatoid vasculitis is present (see",
"    <a class=\"local\" href=\"#H32\">",
"     'Noncardiac vascular disease'",
"    </a>",
"    below), or such manifestations may arise due to dermal infiltration of neutrophils. Atrophic skin over involved joints is sometime present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Rheumatoid nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palpable nodules are present in 20 to 35 percent of patients with RA. Rheumatoid factor is almost always present in patients with nodules. Nodules are common on pressure points such as the olecranon but can form anywhere within or upon the body (eg, in the lungs). (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Lung disease'",
"    </a>",
"    below.) Most skin nodules need no specific treatment. For painful nodules or for those that interfere with joint motion or that impinge upon nerves, local injection with a mixture of a potent glucocorticoid and local anesthetic may cause regression. Surgical excision of skin nodules is rarely indicated. A more detailed discussion of rheumatoid nodules in the skin and subcutaneous tissues is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29815?source=see_link&amp;anchor=H3#H3\">",
"     \"Rheumatoid nodules\", section on 'Subcutaneous nodules'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Skin ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ulcerative lesions may result from venous stasis, arterial insufficiency, neutrophilic infiltration,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vasculitis (",
"    <a class=\"graphic graphic_picture graphicRef69723 \" href=\"UTD.htm?36/21/37202\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/22\">",
"     22",
"    </a>",
"    ]. Chronic ulcers in patients with RA are often multifactorial and may require aggressive immunosuppression for healing. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Neutrophilic dermatoses'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H32\">",
"     'Noncardiac vascular disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Neutrophilic dermatoses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dermal manifestations associated with sterile infiltration of neutrophils are uncommon; these include Sweet syndrome (",
"    <a class=\"graphic graphic_picture graphicRef53359 \" href=\"UTD.htm?42/60/43972\">",
"     picture 2",
"    </a>",
"    ), pyoderma gangrenosum (",
"    <a class=\"graphic graphic_picture graphicRef53733 \" href=\"UTD.htm?38/17/39187\">",
"     picture 3",
"    </a>",
"    ), and rheumatoid neutrophilic dermatitis (",
"    <a class=\"graphic graphic_picture graphicRef80854 \" href=\"UTD.htm?18/27/18864\">",
"     picture 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30393?source=see_link\">",
"     \"Neutrophilic dermatoses\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Medication-induced skin changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications used to treat RA can cause skin changes. These include skin atrophy and ecchymoses from glucocorticoids, as well as petechiae from medications that cause thrombocytopenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36616?source=see_link\">",
"     \"Hematologic manifestations of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rare cutaneous manifestations include erythema elevatum diutinum, linear bands or annular lesions, urticarial eruptions, and dermal papules which may have various histologic appearances, ranging from edema, vasculitis, or palisading granulomatous inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/23\">",
"     23",
"    </a>",
"    ]. The Raynaud phenomenon is relatively common in patients with RA, affecting nearly one-quarter of patients in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of the Raynaud phenomenon\", section on 'Prevalence'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     EYE INVOLVEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Episcleritis and scleritis occur in less than 5 percent of patients. Uveitis, including iritis, may also occur in RA. Scleritis and peripheral ulcerative keratitis with corneal melt can be devastating consequences of RA. This is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22903?source=see_link\">",
"     \"Ocular manifestations of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In episcleritis, the eye becomes acutely red and painful without a discharge (",
"      <a class=\"graphic graphic_picture graphicRef82109 \" href=\"UTD.htm?13/18/13602\">",
"       picture 5",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/5/80?source=see_link\">",
"       \"Episcleritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In scleritis, there is a deep ocular pain. In addition, dark red discoloration can appear as metalloproteases generated by activated scleral cells degrade scleral collagen (",
"      <a class=\"graphic graphic_picture graphicRef57004 \" href=\"UTD.htm?16/18/16687\">",
"       picture 6",
"      </a>",
"      ), in rare cases down to the uveal layer (called scleromalacia perforans) (",
"      <a class=\"graphic graphic_picture graphicRef51568 \" href=\"UTD.htm?27/18/27937\">",
"       picture 7",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/32/22023?source=see_link\">",
"       \"Clinical manifestations and diagnosis of scleritis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Keratoconjunctivitis sicca, or dry eyes, occurs in 10 to 20 percent of patients as part of the sicca complex (",
"    <a class=\"graphic graphic_picture graphicRef52614 \" href=\"UTD.htm?34/56/35713\">",
"     picture 8",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11287?source=see_link\">",
"     \"Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     LUNG DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations, diagnosis, and management of pleural (eg, pleuritis and pleural effusion) and parenchymal lung diseases (eg, interstitial fibrosis, pulmonary nodules, bronchiolitis obliterans, and organizing pneumonia) that are associated with RA are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26969?source=see_link\">",
"     \"Overview of lung disease associated with rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lung disease caused by drugs or other agents used to treat RA may occur as a result of direct pulmonary toxicity (eg, rarely",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and gold salts) or as a result of infectious complications resulting from immunosuppression (eg, glucocorticoids, antimetabolites, and anticytokine therapies). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30344?source=see_link\">",
"     \"Drug-induced lung disease in rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=see_link\">",
"     \"Approach to the immunocompromised patient with fever and pulmonary infiltrates\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     CARDIAC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically apparent pericarditis and myocarditis are uncommon disorders in patients with RA. There is an increased risk of coronary artery disease in patients with RA, and there may be an increased risk of heart failure and of atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. These issues and cardiac involvement by rheumatoid nodulosis are discussed in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Pericarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the course of disease, less than 10 percent of patients have a clinical episode of pericarditis, although up to 30 percent have echocardiographic evidence of pericardial effusions that are of no clinical significance. The prevalence of pericardial involvement at a single point in time in a group of 30 patients with RA when assessed using transesophageal echocardiography was 13 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/27\">",
"     27",
"    </a>",
"    ]. Other patients have asymptomatic pericardial involvement detected at autopsy. Restrictive pericarditis with tamponade physiology is uncommon and may present a diagnostic challenge.",
"   </p>",
"   <p>",
"    Most patients with symptomatic pericarditis have a positive test for rheumatoid factor in sera. Pericarditis occurs most frequently in patients with active rheumatoid disease and other extraarticular manifestations. As a result, management should be linked to control of the RA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in other nonbacterial causes of pericarditis, glucocorticoids are preferred if maximal doses of nonsteroidal antiinflammatory drugs (NSAIDs) are not effective. High-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) may be required in patients with RA and severe, exudative pericarditis. Surgery may be necessary in some patients with severe constrictive pericarditis and with associated heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=see_link\">",
"     \"Diagnosis and treatment of pericardial effusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Myocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocarditis, which can be either granulomatous or interstitial, is rare in RA and is usually associated with active articular disease and with other nonarticular manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/28\">",
"     28",
"    </a>",
"    ]. Granulomatous myocarditis has higher specificity for RA, while the interstitial form is much less frequent in RA than in SLE. Direct granulomatous involvement of the endocardium can produce mitral insufficiency, while involvement of the conduction system can induce atrioventricular block.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography can be used to assess left ventricular function. Right ventricular biopsy at time of cardiac catheterization may be helpful diagnostically if myocarditis or chronic constrictive pericarditis is considered as a possible cause of heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=see_link\">",
"     \"Clinical manifestations and diagnosis of myocarditis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major differential diagnostic entities to consider in a patient with RA who develops heart failure are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ischemic cardiomyopathy &mdash; The risk of coronary artery disease is significantly increased among patients with RA. Previously unrecognized myocardial infarction or severe ischemia may be a cause of heart failure. Rarely, widespread myocardial dysfunction can be the result of rheumatoid vasculitis [",
"      <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/30\">",
"       30",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Coronary artery disease'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Drug-induced myopathy &mdash; Antimalarial drugs used to treat RA can sometimes cause myopathy. Skeletal muscle and myocardium may be affected. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/9/43161?source=see_link&amp;anchor=H11#H11\">",
"       \"Antimalarial drugs in the treatment of rheumatic disease\", section on 'Neuromuscular and cardiac toxicity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      NSAID-exacerbated heart failure &mdash; Use of nonselective NSAIDs and selective cyclooxygenase (COX) -2 inhibitors may unmask subclinical heart failure due to effects on blood pressure and renal function. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=see_link&amp;anchor=H7#H7\">",
"       \"Nonselective NSAIDs: Adverse cardiovascular effects\", section on 'Heart failure'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link\">",
"       \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rheumatoid nodules &mdash; Valvular insufficiency and heart block may be manifestations of rheumatoid nodules. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Rheumatoid nodules'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Amyloidosis &mdash; Deposition of AA amyloid (secondary amyloidosis) may occur, causing an infiltrative cardiomyopathy. Patients with longstanding active RA are at increased risk for this complication. Concomitant renal involvement with proteinuria or nephrotic syndrome is often present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=see_link\">",
"       \"Clinical manifestations and diagnosis of amyloid cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the rarity of rheumatoid myocarditis, optimal treatment is uncertain. In one reported case of heart failure due to rheumatoid vasculitis with myocardial involvement that was detected by right ventricular biopsy, a favorable response to glucocorticoid therapy was noted [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/29\">",
"     29",
"    </a>",
"    ]. We suggest use of high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (pulse therapy 500 to 1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for three days or 80 mg daily) as initial therapy.",
"   </p>",
"   <p>",
"    Use of an anti-tumor necrosis factor (TNF)-alpha agent could be considered for a patient with mild heart failure or with other manifestations of myocarditis. However, high doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    have been associated with increased severity and mortality when used in patients with severe heart failure of other etiologies, and their use in patients with moderate to severe heart failure should be avoided. Immunosuppressive therapies such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , as used for the treatment of systemic rheumatoid vasculitis, are other options for patients who do not respond to glucocorticoids. The role of biologic therapies in the management of rheumatoid myocarditis is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26968?source=see_link\">",
"     \"Heart failure and left ventricular dysfunction in rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/19/22841?source=see_link\">",
"     \"Treatment of rheumatoid vasculitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Coronary artery disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risks of sudden death and myocardial infarction appear to be increased in patients with RA. Although a higher prevalence of traditional cardiac risk factors may be present in patients with RA than in the general population, epidemiologic data suggest that RA is an independent risk factor for coronary artery disease. Among patients with RA, those with systemic involvement are at a higher risk of coronary events [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/31\">",
"     31",
"    </a>",
"    ]. These data and other issues related to coronary heart disease in patients with RA are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10631?source=see_link\">",
"     \"Coronary artery disease in rheumatoid arthritis: Epidemiology, pathogenesis, and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardiovascular disease is a major contributor to increased mortality among patients with RA. The effect of atherosclerotic coronary artery disease on long-term patient outcomes is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/11/184?source=see_link&amp;anchor=H12#H12\">",
"     \"Disease outcome and functional capacity in rheumatoid arthritis\", section on 'Mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of heart failure in patients with RA is increased about twofold higher than in people without RA. As is the case with coronary heart disease, the increased risk of heart failure is not fully explained by other, traditional risk factors. A discussion of the evidence for an association between RA and heart failure, as well as left ventricular dysfunction, is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26968?source=see_link\">",
"     \"Heart failure and left ventricular dysfunction in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H187567760\">",
"    <span class=\"h2\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for atrial fibrillation (AF), including heart failure, ischemic heart disease, and cigarette smoking, are increased in patients with RA, although the incidence of AF in patients with RA has received little attention. A nationwide cohort study in Denmark involving 18,247 patients with RA followed for a median of 4.8 years found a significant increase in the risk of atrial fibrillation in patients with RA, compared with age- and sex-matched controls from the general population (event rates of 8.2 versus 6 per 1000 person-years) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/26\">",
"     26",
"    </a>",
"    ]. This represented a greater than 40 percent increase in the incidence of atrial fibrillation in RA (adjusted incidence rate ratio 1.41, 95% CI 1.31-1.51).",
"   </p>",
"   <p>",
"    The incidence of stroke was also increased in this cohort of patients with RA. The relative risks of both AF and stroke were increased to a greater extent in younger patients, while the absolute differences in risk were higher in older patients. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Stroke'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid nodules may develop in the pericardium, myocardium, and valvular structures [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/32\">",
"     32",
"    </a>",
"    ]. They may be noted echocardiographically [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/33\">",
"     33",
"    </a>",
"    ]. Symptoms related to the presence of nodules are rare, but syncope or death due to heart block from a lesion situated in the conduction system can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/34\">",
"     34",
"    </a>",
"    ]. Stroke or other manifestations of arterial embolization, as well as valvular insufficiency, may result from nodules on a heart valve [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. The histopathology of rheumatoid nodules in the heart is similar to that of nodules at other sites. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Rheumatoid nodules'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     NONCARDIAC VASCULAR DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular disease can take several forms in patients with RA. Vasculitis of small to medium blood vessels can occur, and higher than expected rates of coronary artery, peripheral vascular, and cerebrovascular disease are also seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The manifestations of rheumatoid vasculitis range from a relatively limited condition, with focal digital involvement alone, to a severe, systemic condition which may resemble polyarteritis nodosa. Both small- and medium-sized vessels can be involved. Rheumatoid vasculitis is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20697?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rheumatoid vasculitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following is a brief summary of some of the varied manifestations that rheumatoid vasculitis can cause:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Distal arteritis that can range from nailfold infarcts (common) to gangrene of finger tips (rare)",
"     </li>",
"     <li>",
"      Cutaneous ulceration, which can resemble pyoderma gangrenosum in severe cases",
"     </li>",
"     <li>",
"      Neurovascular disease, which can lead to a mild distal sensory neuropathy or to a severe sensorimotor neuropathy (eg, mononeuritis multiplex). Neuropathic pain may be a major problem, but this often responds to immunosuppressive treatment in patients with vasculitis-related neuropathy. Other symptoms, such as numbness or local weakness, are more likely to persist.",
"     </li>",
"     <li>",
"      Visceral arteritis, which is identical to necrotizing polyarteritis and which can involve peripheral nerves, as well as the bowel, lungs, heart, spleen, and other organs. Intestinal involvement can begin as minor abdominal pain that can progress to severe pain, a quiet tender belly on examination, bowel infarction, and gastrointestinal bleeding.",
"     </li>",
"     <li>",
"      Palpable purpura, which is rarely found in untreated RA and which, when present, is usually linked to antirheumatic therapy",
"     </li>",
"     <li>",
"      Digital gangrene, the presence of intestinal involvement, cardiac involvement, and mononeuritis multiplex, which are associated with a very poor prognosis (see",
"      <a class=\"local\" href=\"#H39\">",
"       'Nervous system involvement'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Peripheral vascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of atherosclerotic peripheral artery disease appears to be greater in patients with RA than in otherwise healthy individuals. This was illustrated in a study that compared 234 non-smoking North American patients with RA to 102 healthy non-smoking controls [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/38\">",
"     38",
"    </a>",
"    ]. Peripheral arterial abnormalities (an abnormal ankle or brachial index",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    evidence of occlusion of a peripheral artery) were present in a significantly greater proportion of those with RA (19 versus 5 percent). These differences were not explained by traditional markers of cardiovascular risk such as hypertension, diabetes, and hyperlipidemia. However, markers of inflammation (eg, C reactive protein or erythrocyte sedimentation rate) and glucocorticoid use accounted for some of the excess risk seen in those with RA.",
"   </p>",
"   <p>",
"    The presence of other systemic and nonarticular manifestations of RA appears to be an independent risk factor for the development of peripheral vascular disease. This was illustrated in a retrospective study of 609 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/39\">",
"     39",
"    </a>",
"    ]. After adjustment for other risk factors, the incidence of peripheral vascular events was significantly greater in those with severe extraarticular features of RA than in those without these features (hazard ratio 2.29, 95% CI 1.20-4.34).",
"   </p>",
"   <p>",
"    In particular, patients with RA appear to have an up to twofold higher occurrence of venous thromboembolism [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. In one population-based study in the US, the risk appeared somewhat higher in patients exposed to anti-TNF agents, although it was unknown whether this was a drug effect or whether anti-TNF exposure was a surrogate for more severe disease which may itself be related to this increased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/40\">",
"     40",
"    </a>",
"    ]. In another population-based study, conducted in Sweden, the increase in risk among patients with RA compared with the general population could be detected within the year following diagnosis and did not increase further during the first decade of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/41\">",
"     41",
"    </a>",
"    ]. The risk was further increased among patients who required hospitalization, although the increase in such patients with RA was comparable to that in the general population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with RA may be at increased risk for stroke, although the supporting data are not as conclusive as those reporting an increased risk of coronary artery disease. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11129?source=see_link&amp;anchor=H13#H13\">",
"     \"Neurologic manifestations of rheumatoid arthritis\", section on 'Stroke'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Lymphatic obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired lymphatic drainage leading to lymphedema is an unusual extraarticular manifestation of RA. In some cases involving unilateral extremity swelling, lymphoscintigraphy confirmed lymphatic obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. Upper and lower limbs may be affected, and cases of symmetrical swelling have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/43\">",
"     43",
"    </a>",
"    ]. Other causes of lymphedema should be considered before attributing lymphatic obstruction to RA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=see_link&amp;anchor=H802872645#H802872645\">",
"     \"Clinical manifestations and diagnosis of lymphedema\", section on 'Inflammatory arthritis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     KIDNEY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct effects of RA on the kidney are rare and include a focal glomerulonephritis, usually of the mesangioproliferative type without rapid progression of renal dysfunction; possible membranous nephropathy; and rheumatoid vasculitis. Much more common is drug toxicity, since many of the drugs used in RA, including nonsteroidal antiinflammatory drugs, gold,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , can cause renal disease. In addition, patients with longstanding inflammatory disease may develop AA (secondary) amyloidosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37812?source=see_link\">",
"     \"Renal disease in patients with rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     SJ&Ouml;GREN'S SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sj&ouml;gren&rsquo;s syndrome has both a primary form, in which it is apparently the sole systemic disease, and a secondary form, in which it is associated with RA or another rheumatic disease. Symptoms of ocular",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    oral dryness are the hallmarks of this disorder. The clinical manifestations, classification criteria, and diagnosis of Sj&ouml;gren&rsquo;s syndrome are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11287?source=see_link\">",
"     \"Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27306?source=see_link\">",
"     \"Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=see_link\">",
"     \"Classification and diagnosis of Sj&ouml;gren's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     NERVOUS SYSTEM INVOLVEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A range of neurologic abnormalities may be associated with RA, which can involve the peripheral or central nervous systems and which can result from local or systemic factors. Carpal tunnel syndrome is the most common neurologic manifestation, and a compressive myelopathy or radiculopathy can also occur. Patients with instability of the cervical spine, most commonly at the articulation of C1 and C2, are at increased risk for myelopathy and require particular attention. The neurologic manifestations are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11129?source=see_link\">",
"     \"Neurologic manifestations of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41080?source=see_link\">",
"     \"Cervical subluxation in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with rheumatoid vasculitis may experience subtle or more severe neurologic disease, such as mononeuritis multiplex or a symmetric polyneuropathy. Central nervous system involvement is uncommon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20697?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rheumatoid vasculitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     HEMATOLOGIC ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia is commonly present in patients with active RA. Neutropenia, present in Felty&rsquo;s syndrome and in the large granular lymphocyte syndrome, may require therapeutic interventions, while reactive thrombocytosis and eosinophilia generally parallel disease activity and do not themselves require treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/32/18954/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with RA have a mild normocytic hypochromic anemia which correlates with the erythrocyte sedimentation rate and general disease activity. The anemia is that of chronic inflammation, in which there is an inability of the marrow to incorporate stored iron into red blood cells and in which the hemoglobin concentration is rarely less than 10",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36616?source=see_link&amp;anchor=H3#H3\">",
"     \"Hematologic manifestations of rheumatoid arthritis\", section on 'Anemia of chronic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Felty's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Felty&rsquo;s syndrome have seropositive rheumatoid arthritis and neutropenia. Many have an associated anemia or thrombocytopenia, an enlarged spleen, and, rarely, leg ulcers. More detailed discussions of the clinical manifestations, the drug treatment, and the role of splenectomy in Felty&rsquo;s syndrome are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4247?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Felty's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18695?source=see_link\">",
"     \"Drug therapy in Felty's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25572?source=see_link\">",
"     \"Indications for splenectomy in Felty's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Large granular lymphocyte syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The large granular lymphocyte (LGL) syndrome in RA, or &ldquo;pseudo-Felty&rsquo;s syndrome,&rdquo; must be distinguished from Felty&rsquo;s syndrome. Patients with LGL syndrome have many circulating LGLs, neutropenia, splenomegaly, and frequent infections. The LGL syndrome is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/62/5095?source=see_link\">",
"     \"Large granular lymphocyte leukemia in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Lymphoproliferative disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;As has already been noted, large granular lymphocyte proliferation may be present in some patients with RA, and, in a minority, it will progress to LGL leukemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21018?source=see_link&amp;anchor=H113797909#H113797909\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia\", section on 'Autoimmune disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, the risk of lymphoma is increased in patients with RA, both in those treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and in those with active disease who have not been exposed to methotrexate or to other immunosuppressive agents. Longstanding, active disease is the major risk factor for lymphoma in patients with RA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/11/184?source=see_link&amp;anchor=H10#H10\">",
"     \"Disease outcome and functional capacity in rheumatoid arthritis\", section on 'Lymphoproliferative disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/15/20721?source=see_link\">",
"       \"Patient information: Anemia of chronic disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/61/21463?source=see_link\">",
"       \"Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=see_link\">",
"       \"Patient information: Rheumatoid arthritis treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/29/39378?source=see_link\">",
"       \"Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H163096886\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Involvement of the musculoskeletal system other than joints (eg, bone and muscle) and of nonarticular organs (eg, skin, eye, lungs, heart, and others) occurs in about 40 percent of patients with rheumatoid arthritis (RA). Risk factors for systemic, extraarticular disease include the presence of rheumatoid factor (RF), anti-citrullinated peptide antibodies (ACPA), and smoking. Extraarticular involvement in RA is associated with increased severity of disease, with overall morbidity, and with premature mortality. Successful management depends upon control of the underlying joint disease and upon additional strategies. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bone loss in RA is common. It may be generalized, resulting from immobility, the inflammatory process, and treatment effects with glucocorticoids; it also includes periarticular demineralization typical of RA. It is due to the combined actions of prostaglandins and cytokines in association with normal amounts of parathyroid hormone. In the absence of antiresorptive therapy, all patients with RA can be expected to lose bone mineral. The generalized and periarticular osteopenia that affects all patients with RA should lead to a low threshold for therapy to prevent bone loss. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Osteopenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Muscle weakness is a common symptom in rheumatoid arthritis. It may have several, often additive, causes, including synovial inflammation, myositis, vasculitis, and drug-induced myopathy (eg, from glucocorticoids,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      , or statins). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Muscle weakness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common of the cutaneous manifestations of RA is the rheumatoid nodule. Other cutaneous manifestations may arise when rheumatoid vasculitis is present or may be due to dermal infiltration of neutrophils. Atrophic skin over involved joints is sometimes present. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Skin disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms of ocular",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      oral dryness are the hallmarks of Sj&ouml;gren&rsquo;s syndrome, which may occur in association with RA. Eye involvement in RA also may include episcleritis, scleritis, peripheral ulcerative keratitis, and, less frequently, uveitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11287?source=see_link\">",
"       \"Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27306?source=see_link\">",
"       \"Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H20\">",
"       'Eye involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pulmonary involvement in RA may include pleurisy and parenchymal lung diseases (eg, interstitial fibrosis, pulmonary nodules, bronchiolitis obliterans, and organizing pneumonia), as well as lung disease caused by drugs or other agents used to treat RA or as a result of infectious complications resulting from immunosuppression. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Lung disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30344?source=see_link\">",
"       \"Drug-induced lung disease in rheumatoid arthritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26969?source=see_link\">",
"       \"Overview of lung disease associated with rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiac involvement, such as clinically apparent pericarditis and myocarditis, and the presence of rheumatoid nodules in the pericardium, myocardium, or valvular structures are uncommon in patients with RA, although there is an increased risk of coronary artery disease, heart failure, and atrial fibrillation. Vascular disease can take several forms in patients with RA. Vasculitis of small to medium blood vessels can occur, and higher than expected rates of coronary artery, peripheral vascular, and cerebrovascular disease are also seen. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Cardiac disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H32\">",
"       'Noncardiac vascular disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20697?source=see_link\">",
"       \"Clinical manifestations and diagnosis of rheumatoid vasculitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Direct effects of RA on the kidney are rare and include a focal glomerulonephritis, possible membranous nephropathy, and rheumatoid vasculitis. Drug toxicity is much more common. A range of neurologic abnormalities may be associated with RA, which can involve the peripheral or central nervous systems and which can result from local or systemic factors. Carpal tunnel syndrome is the most common neurologic manifestation, and a compressive myelopathy or radiculopathy can also occur. Patients with rheumatoid vasculitis may experience subtle or more severe neurologic disease. (See",
"      <a class=\"local\" href=\"#H37\">",
"       'Kidney disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H39\">",
"       'Nervous system involvement'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11129?source=see_link\">",
"       \"Neurologic manifestations of rheumatoid arthritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41080?source=see_link\">",
"       \"Cervical subluxation in rheumatoid arthritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20697?source=see_link\">",
"       \"Clinical manifestations and diagnosis of rheumatoid vasculitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anemia is commonly present in patients with active RA. Neutropenia, present in Felty&rsquo;s syndrome and in the large granular lymphocyte syndrome, may require therapeutic interventions, while reactive thrombocytosis and eosinophilia generally parallel disease activity and do not themselves require treatment. (See",
"      <a class=\"local\" href=\"#H40\">",
"       'Hematologic abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/1\">",
"      Turesson C, O'Fallon WM, Crowson CS, et al. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis 2003; 62:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/2\">",
"      Myasoedova E, Crowson CS, Turesson C, et al. Incidence of extraarticular rheumatoid arthritis in Olmsted County, Minnesota, in 1995-2007 versus 1985-1994: a population-based study. J Rheumatol 2011; 38:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/3\">",
"      Turesson C, Schaid DJ, Weyand CM, et al. Association of HLA-C3 and smoking with vasculitis in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54:2776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/4\">",
"      Turesson C, Jacobsson LT, Sturfelt G, et al. Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis 2007; 66:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/5\">",
"      Turesson C, O'Fallon WM, Crowson CS, et al. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol 2002; 29:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/6\">",
"      Gabriel SE, Crowson CS, Kremers HM, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003; 48:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/7\">",
"      Turesson C, Matteson EL. Management of extra-articular disease manifestations in rheumatoid arthritis. Curr Opin Rheumatol 2004; 16:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/8\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/9\">",
"      Marotte H, Farge P, Gaudin P, et al. The association between periodontal disease and joint destruction in rheumatoid arthritis extends the link between the HLA-DR shared epitope and severity of bone destruction. Ann Rheum Dis 2006; 65:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/10\">",
"      Compston JE, Vedi S, Croucher PI, et al. Bone turnover in non-steroid treated rheumatoid arthritis. Ann Rheum Dis 1994; 53:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/11\">",
"      Laan RF, Buijs WC, Verbeek AL, et al. Bone mineral density in patients with recent onset rheumatoid arthritis: influence of disease activity and functional capacity. Ann Rheum Dis 1993; 52:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/12\">",
"      Haugeberg G, &Oslash;rstavik RE, Uhlig T, et al. Clinical decision rules in rheumatoid arthritis: do they identify patients at high risk for osteoporosis? Testing clinical criteria in a population based cohort of patients with rheumatoid arthritis recruited from the Oslo Rheumatoid Arthritis Register. Ann Rheum Dis 2002; 61:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/13\">",
"      Kr&ouml;ger H, Honkanen R, Saarikoski S, Alhava E. Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis--a population based study. Ann Rheum Dis 1994; 53:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/14\">",
"      Sinigaglia L, Nervetti A, Mela Q, et al. A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. J Rheumatol 2000; 27:2582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/15\">",
"      Haugeberg G, Uhlig T, Falch JA, et al. Reduced bone mineral density in male rheumatoid arthritis patients: frequencies and associations with demographic and disease variables in ninety-four patients in the Oslo County Rheumatoid Arthritis Register. Arthritis Rheum 2000; 43:2776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/16\">",
"      McDougall R, Sibley J, Haga M, Russell A. Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls. J Rheumatol 1994; 21:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/17\">",
"      Rold&aacute;n JF, Del Rinc&oacute;n I, Escalante A. Loss of cortical bone from the metacarpal diaphysis in patients with rheumatoid arthritis: independent effects of systemic inflammation and glucocorticoids. J Rheumatol 2006; 33:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/18\">",
"      Lowthian PJ, Calin A. Geode development and multiple fractures in rheumatoid arthritis. Ann Rheum Dis 1985; 44:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/19\">",
"      &Oslash;rstavik RE, Haugeberg G, Mowinckel P, et al. Vertebral deformities in rheumatoid arthritis: a comparison with population-based controls. Arch Intern Med 2004; 164:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/20\">",
"      Halla JT, Koopman WJ, Fallahi S, et al. Rheumatoid myositis. Clinical and histologic features and possible pathogenesis. Arthritis Rheum 1984; 27:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/21\">",
"      Sayah A, English JC 3rd. Rheumatoid arthritis: a review of the cutaneous manifestations. J Am Acad Dermatol 2005; 53:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/22\">",
"      Oien RF, H&aring;kansson A, Hansen BU. Leg ulcers in patients with rheumatoid arthritis--a prospective study of aetiology, wound healing and pain reduction after pinch grafting. Rheumatology (Oxford) 2001; 40:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/23\">",
"      Sangueza OP, Caudell MD, Mengesha YM, et al. Palisaded neutrophilic granulomatous dermatitis in rheumatoid arthritis. J Am Acad Dermatol 2002; 47:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/24\">",
"      Pope JE, Al-Bishri J, Al-Azem H, Ouimet JM. The temporal relationship of Raynaud's phenomenon and features of connective tissue disease in rheumatoid arthritis. J Rheumatol 2008; 35:2329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/25\">",
"      Gabriel SE. Heart disease and rheumatoid arthritis: understanding the risks. Ann Rheum Dis 2010; 69 Suppl 1:i61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/26\">",
"      Lindhardsen J, Ahlehoff O, Gislason GH, et al. Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study. BMJ 2012; 344:e1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/27\">",
"      Guedes C, Bianchi-Fior P, Cormier B, et al. Cardiac manifestations of rheumatoid arthritis: a case-control transesophageal echocardiography study in 30 patients. Arthritis Rheum 2001; 45:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/28\">",
"      Sigal LH, Friedman HD. Rheumatoid pancarditis in a patient with well controlled rheumatoid arthritis. J Rheumatol 1989; 16:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/29\">",
"      Slack JD, Waller B. Acute congestive heart failure due to the arteritis of rheumatoid arthritis: early diagnosis by endomyocardial biopsy: a case report. Angiology 1986; 37:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/30\">",
"      Fischer LM, Schlienger RG, Matter C, et al. Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol 2004; 93:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/31\">",
"      Turesson C, McClelland RL, Christianson TJ, Matteson EL. Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/32\">",
"      Kitas G, Banks MJ, Bacon PA. Cardiac involvement in rheumatoid disease. Clin Med 2001; 1:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/33\">",
"      Wisowska M, Sypua S, Kowalik I. Echocardiographic findings and 24-h electrocardiographic Holter monitoring in patients with nodular and non-nodular rheumatoid arthritis. Rheumatol Int 1999; 18:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/34\">",
"      Ahern M, Lever JV, Cosh J. Complete heart block in rheumatoid arthritis. Ann Rheum Dis 1983; 42:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/35\">",
"      Chatzis A, Giannopoulos N, Baharakakis S, et al. Unusual cause of a stroke in a patient with seronegative rheumatoid arthritis. Cardiovasc Surg 1999; 7:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/36\">",
"      Mounet FS, Soula P, Concina P, Cerene A. A rare case of embolizing cardiac tumor: rheumatoid nodule of the mitral valve. J Heart Valve Dis 1997; 6:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/37\">",
"      Kang H, Baron M. Embolic complications of a mitral valve rheumatoid nodule. J Rheumatol 2004; 31:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/38\">",
"      del Rinc&oacute;n I, Haas RW, Pogosian S, Escalante A. Lower limb arterial incompressibility and obstruction in rheumatoid arthritis. Ann Rheum Dis 2005; 64:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/39\">",
"      Liang KP, Liang KV, Matteson EL, et al. Incidence of noncardiac vascular disease in rheumatoid arthritis and relationship to extraarticular disease manifestations. Arthritis Rheum 2006; 54:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/40\">",
"      Bacani AK, Gabriel SE, Crowson CS, et al. Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events? Arthritis Rheum 2012; 64:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/41\">",
"      Holmqvist ME, Neovius M, Eriksson J, et al. Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. JAMA 2012; 308:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/42\">",
"      Sant SM, Tormey VJ, Freyne P, Casey EB. Lymphatic obstruction in rheumatoid arthritis. Clin Rheumatol 1995; 14:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/43\">",
"      Joos E, Bourgeois P, Famaey JP. Lymphatic disorders in rheumatoid arthritis. Semin Arthritis Rheum 1993; 22:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/44\">",
"      Kiely PD, Joseph AE, Mortimer PS, Bourke BE. Upper limb lymphedema associated with polyarthritis of rheumatoid type. J Rheumatol 1994; 21:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/32/18954/abstract/45\">",
"      Panush RS, Franco AE, Schur PH. Rheumatoid arthritis associated with eosinophilia. Ann Intern Med 1971; 75:199.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7511 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-88.81.100.162-2094B74F85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_32_18954=[""].join("\n");
var outline_f18_32_18954=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H163096886\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OSTEOPENIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MUSCLE WEAKNESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Synovial inflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Myositis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Drug-induced myopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Antimalarial drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Lipid-lowering drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SKIN DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Rheumatoid nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Skin ulcers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Neutrophilic dermatoses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Medication-induced skin changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      EYE INVOLVEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      LUNG DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      CARDIAC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Pericarditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Myocarditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H187567760\">",
"      Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      NONCARDIAC VASCULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Peripheral vascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Lymphatic obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      KIDNEY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      SJ&Ouml;GREN'S SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      NERVOUS SYSTEM INVOLVEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      HEMATOLOGIC ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Felty's syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Large granular lymphocyte syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Lymphoproliferative disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H163096886\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7511\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7511|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/21/37202\" title=\"picture 1\">",
"      Rheumatoid leg ulcer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/60/43972\" title=\"picture 2\">",
"      Sweet syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/17/39187\" title=\"picture 3\">",
"      Pyoderma gangrenosum early",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/27/18864\" title=\"picture 4\">",
"      Rheumatoid neutroph dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/18/13602\" title=\"picture 5\">",
"      Episcleritis in RA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/18/16687\" title=\"picture 6\">",
"      Diffuse scleritis in RA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/18/27937\" title=\"picture 7\">",
"      Necrotizing scleritis in RA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/56/35713\" title=\"picture 8\">",
"      Ocular adherent filaments",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=related_link\">",
"      Anemia of chronic disease (anemia of chronic inflammation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/9/43161?source=related_link\">",
"      Antimalarial drugs in the treatment of rheumatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=related_link\">",
"      Approach to the immunocompromised patient with fever and pulmonary infiltrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41080?source=related_link\">",
"      Cervical subluxation in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=related_link\">",
"      Classification and diagnosis of Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=related_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4247?source=related_link\">",
"      Clinical manifestations and diagnosis of Felty's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=related_link\">",
"      Clinical manifestations and diagnosis of amyloid cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=related_link\">",
"      Clinical manifestations and diagnosis of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20697?source=related_link\">",
"      Clinical manifestations and diagnosis of rheumatoid vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/32/22023?source=related_link\">",
"      Clinical manifestations and diagnosis of scleritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=related_link\">",
"      Clinical manifestations and diagnosis of the Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11287?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27306?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21018?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10631?source=related_link\">",
"      Coronary artery disease in rheumatoid arthritis: Epidemiology, pathogenesis, and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11128?source=related_link\">",
"      Diagnosis and evaluation of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=related_link\">",
"      Diagnosis and treatment of pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/11/184?source=related_link\">",
"      Disease outcome and functional capacity in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18695?source=related_link\">",
"      Drug therapy in Felty's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30344?source=related_link\">",
"      Drug-induced lung disease in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=related_link\">",
"      Drug-induced myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=related_link\">",
"      Epidemiology and clinical manifestations of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/5/80?source=related_link\">",
"      Episcleritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23173?source=related_link\">",
"      Glucocorticoid-induced myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26968?source=related_link\">",
"      Heart failure and left ventricular dysfunction in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36616?source=related_link\">",
"      Hematologic manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25572?source=related_link\">",
"      Indications for splenectomy in Felty's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=related_link\">",
"      Initial treatment of dermatomyositis and polymyositis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/62/5095?source=related_link\">",
"      Large granular lymphocyte leukemia in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11129?source=related_link\">",
"      Neurologic manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30393?source=related_link\">",
"      Neutrophilic dermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13591?source=related_link\">",
"      Nonpharmacologic and preventive therapies of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=related_link\">",
"      Nonselective NSAIDs: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22903?source=related_link\">",
"      Ocular manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26969?source=related_link\">",
"      Overview of lung disease associated with rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41210?source=related_link\">",
"      Pathogenesis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=related_link\">",
"      Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/15/20721?source=related_link\">",
"      Patient information: Anemia of chronic disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/29/39378?source=related_link\">",
"      Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/61/21463?source=related_link\">",
"      Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=related_link\">",
"      Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37812?source=related_link\">",
"      Renal disease in patients with rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29815?source=related_link\">",
"      Rheumatoid nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=related_link\">",
"      Statin myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/19/22841?source=related_link\">",
"      Treatment of rheumatoid vasculitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_32_18955="Desens sol std";
var content_f18_32_18955=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F50123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F50123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Solutions for standardized desensitization protocol (using an example of a target drug dose of 1000 mg)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Solution",
"      </td>",
"      <td class=\"subtitle1\">",
"       Volume in mL",
"      </td>",
"      <td class=\"subtitle1\">",
"       Concentration",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dose (mg) in solution",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       250 mL",
"      </td>",
"      <td>",
"       0.04 mg/mL",
"      </td>",
"      <td>",
"       10 mg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       250 mL",
"      </td>",
"      <td>",
"       0.4 mg/mL",
"      </td>",
"      <td>",
"       100 mg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       250 mL",
"      </td>",
"      <td>",
"       4 mg/mL",
"      </td>",
"      <td>",
"       1000 mg",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The above three solutions are required for the standardized protocol for drug desensitizations for immediate hypersensitivity reactions. Solution 3 is the normal intravenous preparation of the drug as it is usually administered (ie, 1000 mg in 250 mL). Solution 2 is a 10-fold dilution of solution 3, and solution 1 is a 10-fold dilution of solution 2. Note that if the full amount of all three solutions were administered, a total of 1110 mg would be given. To avoid this, only part of solution 3 is infused.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mariana Castells, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_32_18955=[""].join("\n");
var outline_f18_32_18955=null;
var title_f18_32_18956="Isopropyl alcohol intoxication - Rapid overview";
var content_f18_32_18956=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Isopropyl alcohol intoxication: Rapid overview",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (",
"        </span>",
"        <a href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">",
"         www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"        </a>",
"        <span style=\"color: #ff0000;\">",
"         ).",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical and laboratory features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients with isopropanol toxicity generally present with an alteration in mental status similar to that seen in ethanol intoxication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rarely, massive overdose may present with hemodynamic instability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diagnostic evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fingerstick glucose, salicylate and acetaminophen levels, and an ECG should be obtained",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Basic electrolytes (with calculation of anion gap), BUN and creatinine, serum and urine ketones, serum osmolality, and an arterial or venous blood gas should be obtained",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum isopropyl alcohol level should be obtained if possible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laboratory hallmarks of isopropanol poisoning include an elevated osmolal gap",
"        <strong>",
"         without",
"        </strong>",
"        an anion gap acidosis, and a severe ketonemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Most patients recover uneventfully with supportive care alone; gastrointestinal decontamination with activated charcoal is unnecessary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Profoundly intoxicated patients may require endotracheal intubation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypotension should be treated with intravenous crystalloid, followed by vasopressors if needed. Refractory hypotension (which is very rare) is an indication for hemodialysis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isopropanol does NOT cause a metabolic acidosis and is NOT associated with the significant toxicity that may be seen in methanol or ethylene glycol ingestions. Aggressive alkalinization and/or antidotal therapy with fomepizole or ethanol are NOT INDICATED in isolated isopropyl alcohol ingestions.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_32_18956=[""].join("\n");
var outline_f18_32_18956=null;
var title_f18_32_18957="Muscular dystrophy PI";
var content_f18_32_18957=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F61217&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F61217&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Most common forms of muscular dystrophy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_left\" colspan=\"2\">",
"       Duchenne and Becker muscular dystrophy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       When do they start?",
"      </td>",
"      <td>",
"       Duchenne and Becker muscular dystrophy are very similar. Duchenne usually starts by age 2 or 3 years. Children with Duchenne are usually in a wheelchair by age 12. Becker causes similar symptoms but starts later and is usually less severe.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Who does it affect?",
"      </td>",
"      <td>",
"       Mostly boys, but it can affect girls some, too",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Which muscles are affected most by weakness?",
"      </td>",
"      <td>",
"       Weakness starts in the trunk but spreads to the arms and legs. The legs usually get weak first. This can make it hard to run, jump, or climb stairs.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       What other problems can it cause?",
"      </td>",
"      <td>",
"       <p>",
"        Heart and lung problems",
"       </p>",
"       <p>",
"        Abnormal curves in the spine",
"       </p>",
"       <p>",
"        Mental problems in some but not all children",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_left\" colspan=\"2\">",
"       Emery-Dreifuss muscular dystrophy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       When does it start?",
"      </td>",
"      <td>",
"       Ages 10 to 20 years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Who does it affect?",
"      </td>",
"      <td>",
"       Boys and girls",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Which muscles are affected most?",
"      </td>",
"      <td>",
"       Weakness starts in the arms and later affects the legs, too. Sometimes the face weakens a little.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       What other problems can it cause?",
"      </td>",
"      <td>",
"       <p>",
"        Heart problems",
"       </p>",
"       <p>",
"        Limited movement at certain joints caused by a tightening of the tissues around the joint (called \"contracture\")",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_left\" colspan=\"2\">",
"       Myotonic dystrophy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       When does it start?",
"      </td>",
"      <td>",
"       Teenage years or later",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Who does it affect?",
"      </td>",
"      <td>",
"       Boys and girls",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Which muscles are affected most?",
"      </td>",
"      <td>",
"       Face muscles, arms, and legs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       What other problems can it cause?",
"      </td>",
"      <td>",
"       <p>",
"        Muscle pain",
"       </p>",
"       <p>",
"        Problems affecting the heart, eyes, brain, and sexual organs",
"       </p>",
"       <p>",
"        Problems breathing and swallowing",
"       </p>",
"       <p>",
"        Stomach pain, diarrhea and constipation",
"       </p>",
"       <p>",
"        Being too sleepy during the day",
"       </p>",
"       <p>",
"        Nerve damage (called neuropathy)",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_left\" colspan=\"2\">",
"       Limb girdle muscular dystrophy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       When does it start?",
"      </td>",
"      <td>",
"       Childhood or later",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Who does it affect?",
"      </td>",
"      <td>",
"       Boys and girls",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Which muscles are affected most?",
"      </td>",
"      <td>",
"       Shoulders and hips",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       What other problems can it cause?",
"      </td>",
"      <td>",
"       <p>",
"        Heart problems",
"       </p>",
"       <p>",
"        Limited movement at certain joints caused by a tightening of the tissues around the joint (called \"contracture\")",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_left\" colspan=\"2\">",
"       Facioscapulohumeral muscular dystrophy (FSHD)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       When does it start?",
"      </td>",
"      <td>",
"       Usually affects people ages 20 to 30 years, but can happen younger",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Who does it affect?",
"      </td>",
"      <td>",
"       Boys and girls",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Which muscles are affected most?",
"      </td>",
"      <td>",
"       The face muscles get so weak that the person cannot smile, whistle, or shut his or her eyes tight. In some cases, weakness affects the legs; in other cases, the shoulders and upper arms.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       What other problems can it cause?",
"      </td>",
"      <td>",
"       <p>",
"        Vision or hearing problems",
"       </p>",
"       <p>",
"        Heart problems",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_left\" colspan=\"2\">",
"       Congenital muscular dystrophy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       When does it start?",
"      </td>",
"      <td>",
"       At birth",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Who does it affect?",
"      </td>",
"      <td>",
"       Boys and girls",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Which muscles are affected most?",
"      </td>",
"      <td>",
"       Many muscles can be weak. Sometimes this is called \"floppy baby\".",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       What other problems can it cause?",
"      </td>",
"      <td>",
"       Limited movement at certain joints caused by a tightening of the tissues around the joint (called \"contracture\")",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_32_18957=[""].join("\n");
var outline_f18_32_18957=null;
var title_f18_32_18958="Age at onset of ILD";
var content_f18_32_18958=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 491px\">",
"   <div class=\"ttl\">",
"    Age at onset of presentation in different interstitial lung diseases",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 471px; height: 283px; background-image: url(data:image/gif;base64,R0lGODlh1wEbAcQAAP///wAzmYCAgCBzOf8AAAAZTAAAABA5HH8AAMDAwEBAQBAQEDAwMHBwcNDQ0PDw8ODg4CAgILCwsKCgoFBQUJCQkGBgYD8AAAgcDgAMJgAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADXARsBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIViEgICECKIFYuGkJGSTA8MBgwMCQANlwsLj5OhoqM6FgYVIw8GCwAVBg2ksbKzLAsGCpcQCbcAuwq0wMGzBgYJpha+vby9ic3Oz9DR0tPU1dbX2Nna29zd3t/g4diawk+2ygoOlwASBhQiCQoK4vT19vf4+fr7/ALzJQm+kSsXw5QAgwAiGJBAwcCEEYkISnwSkYSADAUyatzIcWMGARNhPGj4SoQDSwtg/0EEGbIlkooQCwSYSbOmzZoFWLrcAXOnTyA9AQiQebOozZw/dQRNyhRH0KFGo85E2tTG0qpYYzwlKrUo1awx4ukES9bF1q5Gv5ZtIXat2xVn0d5UCzCBXRUNfj25WwKRAAcAHiQADMBBggdbrr5dHFcuzrEliBFbQNgELijESFSSXCwZAFwDsShe7Lax46mQSWR29U7AQ6EPL0MQIMFCOgkKVLZSQEGCCNcVFFhAnICCPFSzE0iYgGjRBAGIR2QecezBgwqGl4FOnJr0W9On6ao2gA7AMl6Xd91aFUHhQ04NGvomxkChBaEW/DncZUvBhFMALBBBZOSNYEt08BgQQf8iCoV2xWjekQWeY+JJZ4AAljx03i/pXfgZebuAtAADgblj3i+qoFgBBZYIsItKD4zYDirj1UiCepw5aAWEEWY1oVwVikCMPK9t+KEyIHUIkpFGMrBABa646KEIpliCoJAFitCgCNZ5tl0WbfVI2o9oBWleliLY0oApHILooZIAyCcAgExGkAAnUuqk3jsENgPAfyk1YKeXxWgRppjfQQbVaTSZOd0IE3jCSZtIHhliYA2lJKRevPy3Xp4kKOQbgZKJUIFC7uiiXaFa8IgoU2R2ZaYVqgxoh6uv/hSrVLNWEeUduOa6065R9epdsMK2RGxa3SGKbA8BUaNjsmks61X/sz0emsRFHWn0EbVuWDsXthFq+xJX44LbxlMYdeuut+RG+CwPi16rLhtBRdvNtM7GG0S96d6rxrwCp0CwUuge5W/BXRzMcAkOO5XwYw+fEXHFQi38A8AKY1zGxQ+bewTHFHs8BsgMi2wEyY1qbHIVKDMc8wwso/ayGDMLnLNWE7fMg77S8HszDD0BvY3QTBlm12GMCOCIRS73UHMAxhLdbrffDm3VWAJgcMDXYIctdtgYRB0SLpJpwomTn6zExNRVvwC32VpDzPUBA+St9958730A3RLhUoFd1q3SSkm/AZ7D3PT2bHPdNPQkAN59V873327hwoB/5XmW8duOU604/wqMQ07z3ZannjfmazUgQAO2SJCMZyoXUTrCxY5et+SUq145699dqA6J7fBZOxG3Lx563KbbbVHvvl9Orl+j4pBXCROk00L2lZURQQOwFypqQ699vkTyEufevAy8R/97s5sp0GIOz0HM6goBgVIGSRG8dtIqujGfEtB3AwKuDy6oc5/0SIc4B/gmL8IBTEAcMAFNGCOC7DAOjepXGONsxwG2aUB0gpMbXSiiMLahQPnesDOiLU93JjDgAQ2WQAXqDXjYG9JftPQ6AQllFRfaBQP8QRt3wOdIEPCEfhKQxCGOCACmcF0m5sTESxyET3Boodxe2Dj1zdAsNbThAHAIMf9bEOMhd1LAOeY0qoY8AgINQYyTjuSKh1DRFQ80gAMaQgEX/XAwCmpABa4ULhjWQIaR4+IXW9A+Ma4OfiaZVPEkYIk/iuAyI8DkZS5DxT92kooPsIAlFtJJ3NiCRHA43hAQSTNFLhKBz3PkI0nnH2NcaE60UYglD4eMRESpeJZyRzyKoQ4KJCACrLDA4DhRASoaQ3aeiIMqhcBK9rnylTSMpSzJOIJhKggkm2kPeTr5G4Us4IG2oABiMMmJERVqAgphAGAEYAtNURECo5SnHLRolmumj1nYhCVEoGdDbuaKn4z0ZwEVGlCoadORBn0VQllQTZ55saEnaCREDdmUicL/haGHBClGNSrGiPYLdBdVXkox6tCBynKMHE3KNP8l0laulKWJe2hJY/qTmQKlpta8KU5JWlCe6sqoLhRqSJU6Uq55bWxQFVvZ7uVRFVQ0qQDFqfO6KRCqInWLTLVpVrXqtqaidKwqRStZq0qKCUxgJPfxAVtJB1SLqlWrcxVFBCpgCgD97B/nqytW7UXWskaoGJu73l+/2s+wBvWuQ2UsLRaAS3/IVbIUFSxYIcvSvIaCE4iNK70w+9FizWMaSMuoZr/o2UlcRwIP2KHUSGvV5T0VqlMdbMAKK0BmeCO1n31NMy97Vq8Q1G9mu+oiJXcBBDj3udCNLnQvQNs4CIYB/8gojl5GW9y5HPeGyV3tDCWHAAKY97zoTS96EVDdVHKGGKLVgU83trzvzlK3HeNtbwVQXvX6N73sDcZsInDaQUILsAOsb+pMSlfHYpO8/42weQMsjOUEhmmz7e5R7AtTuxKWtxCW8H8pbAJdLA0AJmYil5bGlzww4B0PiEB8ldJe1RaLwwy2MWdbYjRoABcoXOuviNVLYvuVak6SuQ+OHoUHVln2BbqoTCP011qLKNhyOY6heIEhgOZK17nUfVuQh+zfIgNkGbiMsR6FeGI9PEkEFMAiC+IngrV5AhRVjsmNFxxeBxOEvxE288jGTGYAY8szuPyQXb7pmj1UKUMvAP8tigznCt3k+TdXfp+Hd5sUQI+4xjEkdKHPK+huovkWnBjQkreLh1AC8AUh4sXsltHbc+0Zy33ecUg8XWZQb/U3Qh41AUqdIL3MicAWWITn+CCYZrcgxg2Y9S9oh+BtZbpvWYbYlmnBayL7uqXAFjapmwUBV2Tih2NZth48lQAGBDAFS77F8Nhhol5U29ZpwXGuP9zpYBtazBbxd6GJjeTMJNrUrNZDBOoTkISjQDAJMDdgxucQw1r71prGb8lgJfBxAxwiHR8ysUlRDAWkEQae+Z+mLI5v4/J50/nleKC/bfFuj3rko5CxE9+9OJpjGuPY3jendRXyYft8v0WXMM7/RdGOyeiPxhrGib5hvvF+z/zj4Ra30QniAKc9HeqBBfoCNe6zjhZ96f8StbDRTpr5yvXaY98sv4l+9fOp/eZHR0PJ3xuB7t3A7VKDO3KpXnaZfxrrQkl63WmRDgUQWB64kLNTjg63qZP9cYbvNeJtPvC8p6EBK3wy2BMs9sFfXnRV4bzH7W4RL3/59WD2fBoEQ5gErHDyUW+U5eU+dJ+ofsKUT3dXheGpSxCy57mfyu4bq+uJ/H7rrO+RgF5ngBkjP+z5fvnpmReM57N9Y7IXxALIodgdAL6L2cc14TFv9cNHv+3GiLYxJI+D8/NE8OBdP+rNvvhthf8P7zUkxIV9/y6nftv3f/t0dsEnL9Bwe9dHeumXcbwXc+2nee/nHUpjF373gBcXgUGnf9zHZQqIeKSBNgKYYQToXdo3gVVHd+43QAj4B8+RCH7FXSm4YSvIfHPneyN4gWIiHAdGefh3XyxYeBXobSS4GEojAQvgcH93byMzhB12gKnXgzD4g5zxVZcmFFKYbVbmZ+XgfQvYIzPYaAMIgQUogTrYe8Nihf4nJg4AGBXggBzYcipogEXIfi5ogVfYI+6GZNXDE0JYevlHhfz3gm/YIyX3YvSHezcodTmYUGAoDGKYhG+xEK8gevIFhSvThUJHgXuIhD64GCQxAXEWhMlHNcsnic0nEf+VOIpvAUcipACBOHodmIYfaIiZJ4p92FBbWHmRmFmT2H1u+BIxSAsQ8BxP0zTLmFOPqHvBWFqt+GfFOGhDY4ILgBh21jbOiIZ3qIasuINt2H/GGCHp4ABfxwKwtRmHQWmIU2tRSIhEuIagyIPkaI3esRCcyAKz0YSdQ2u/6IkgeIwsVI0rQ5AKF4BOiAIOoEYKIBiytgz2hzseGHf02IL2iIjliIEUICCQx3NwITzrAEz2NogVaXp5uH+7+G+w6BYVJAPfQ08VR3HlE5DyOIUpGYLcZpC2g5B80HXNyAIkQVkmgRIBZJMnWYg56ZP4wpPIw5R5UHyUcYa3+I25uJT/VXiPBykmC2BMlNSIBWSSuGiR4ciGLvGKvZiP5KCJtmiHOIiHF2mEociSaUka9dFDIGkDE5lWY4mScamHGcmHiRghDmBGDHB8TyiWVkmWwjiNYeiUqwSVejAYQJaKBbCKjekVp4VaYGINP7ZKkElNkqksivmW4JiZc3FbuAWV3PIuWeMEaDmYAYWUfamUf6mKquOFzyiX5xOaaddZpQmJcFmWpnmaUzA1KtkEsbmREQI+ommZmCmNtWmbMBM6yfk2vlmZPWIbQbCX/zSdOHmbl5mbrGmdOilX2Ql+YlIBlJUIdKiX+4g8Arl9HBae1ckr4bec+GiOnLGQWwOd0Vhb/zdpn1SAnOcpNelJlaSRgZSJgt5YnIwpnYsZofBWDZ95m9fZm1rZk4jSHLJlgw8qnMYpoElJnXBxNR3xmnwpjtuSoA7qHaBVHNbniCEKjcOJmhBKoQ3mmBh6oPTioiDqHQsgSg2noPFYogQqoTnqlziKkVZhnodmoUoBpIIoJiV3Qai4m7h5o0oqoiO6oyyaSPhpMK4nXWG2OFTaloshPxHQEDRifvG5SvOZk/Wpm1w4jE3qpFknmFaRpnWohIaJmGEJoFxKouCZpAazbYYapvoZOX5Ko9mygWraiTdpp3eKpIgKpmYppkzVqDTzqIPaIw+QF72hnlo6noWaqANqp//K1aPY4qnsA6r/2SMmuBBGSqlIaqnAGKCaWo9POqakI6sgt6FPaaXgtDm3ajtzKp51GjWtSpy+uqe8WEDCGjmjaQe0+Bv+SQPeuVCV+oleepXQypu/2qnVmnjEGpnmyKby0KZZWqPKx6u9Gq46qmNhKlY7Bqtaca7sc61zEIC0VqWnGp2LuqQmWrB6yqn5eq76+pxmNbDyaq8TyqRdSq5LZa7pSjT8qhX+SgfX0QzvaQIPMIOgMGXgVpUGm6nzaqOpKrHRqrCMyrAbSzQdOweocoIUJRlts414FpwsK67jGq8Rq214WrEWi64aeUgzKzc1KwfCpIEuoGINAR3uaGn/Piu0X7qyWJu1Wla0CJuwDSs3SwtGYrImNWAKFRSR20WbEzuPQbulLdu1PPq2GTqsSeuoGfubZNifMDBv0gYPcUpNy/q2qBq3RDu3eXq0YWsWY8tITRsHq/CRLxAph1kYI1lv3Vqu4KmrUqiycnuvj7Wwecu4o2uqEbIgMuAKKdFoNMlyR7q54PqzQGu0dXuxonu3n1q6ydo6C+KeLlCrv6ByR3m1cDu7tFu4XHu4oKt/tYu0fKq0uvuiJci30vu6beu5n3u92PuFiEu7zbu4jNS4FPW4cMCgkhqq8Fq89eqy9EqxXwuYmhuz0WtV4itQvki8yLu+2Zuy26tn3fu+//ArrXRJrfMrsPwpGds6A5lru9fLuavqrIqqqhiLu7FawJPqFhCEC3lZAwsMsynrwJjKqhGstQHsvNPapxb8pxEyRLsrp98Kgs2qiyu6qeBLURvbY88wEFsYCTGWwKdDqMmrvNorwl4rwbf7vHhLwTRTptF1pvD4FrU6o+iLsu3rtomrvvrLvct7et8rsykcrIu3w4SQwcPRwoL7wvRJnjL8nfKrxBr7xRllhWIsIfhLsEY8xBBcxCTcxXAccH0MMXJMvm3QYyHLrYFLU2hMp2qMlfcHrHH8xwK8XkaFlnMMCAWHwO9KxbLrvgCcv1nsv1ucknzsxmILyXbLh5X8B/8mBk+r8KYGrMlb+8mgjMdr7K0TjMS5S8pv/IKpDAjsWX3pCKluWcX9O8v8S8RpsZlBw8VmUsNwsbGULMhs8D/npp3p68kH28kxnJOqOTa55aoG48W6XMq8LM1rgGSQlxtmjMi5GruxLMuXeqjIfMQnDL3jTLrlLC8Kuc4/lcjMusj/PLRa3Ma4XMH3HL5hbM6x0MH42sDujMWcTMLYnM173MziXNC5jMoKTQoMHboODcMATbjbDM5gfND0a8qRvHpPzFp1LNADfcx5HMIxTc8DjMIm/cwJDZxcJS3oB7sg7dI/J9PM/KoXXc82rdE6/RsoyhEqysYf/NATbcXaHNL/VzzKGL3LV72vOf2w8bypDf3UP224L03MxdzVNFzUNU3A+czVz3rFUQ3C8jzTtCzKFm3KzmzDWx1Qh9LWx2vHEj3SIk3V3lvXN13SWY3VvNjLTbHXI8y+m0zRfy3YUw3UZv2ydx3OKG3CdKnYHaUTfD3ZQTzWjw3Z+0vW80zQRp3RqZ3ESM3WjV3ao13WlR3bZb2rWKbMPibEc4HbzqAAaC3JP5rXN2MYJGCyhvXZdwzWaUzZtv07TDxdimKe3Uw2v63SaCrcHpOM51BnncCNAoTckS3Wov3OEe3Y5H1DxWigOFbdwBfca/0yBcclVXvcr63bxAzXcx3QWJbe5rne/3YNzYFcN9Pxt90I3uYN0VIN2qEd1PLM37zi34X9yBFu2Im90YAw4GoLuJ5d3+ON4LLd3Mab3Kbt4JXK3tA3pdhtMtMxbyTJ2Hp84G8N1YDt1nVK4rlq4t+Hz639MqpSDIvQugXO4cZ83zIu2SJO2wdg45uL45Mc4DdzySAhvOBm4LB93h/euad9zErewEzu3js+mxv+4lXu4fgN08u93+So3gvW5Tzh5Pc75Ef71UQe1gs+21Y+Rlv+wWyO4u8N5nBewnIe22Vu2nKt5Wne32v+35kdzRjl4v975FY+6Ehe6CN+6A+e6BMOyIvu5tjk6KGs3yEO6R5e21ie5/e95//X3ecPFuaPHt51buejnuWVrpFqjuaZ7se3rumq/kowQeX2LehFztylbuklrui5jutfvup/3ryBHunBLt4MPsSmLuio7hScruzR/rLNTubPXucgfjnTHunVrtbJzuusrpk8feah7urePuy0jui2ftgIfeynXOGNjmBwM91g882gDs+wHtWkvqrhTubjftT23lCe/tHq7u/fXt5jDvBJTuw3buzyruMH/+bZPucL7/APP+N9nZsD/9YFb8/lvlznrvCKDO0ZP+kb7zchD+EVj9P0ntLt3Y1+vvLOTucMj+WUjuQvj+kxf9Izr9nAbfPY/u9+DeNJ3/FGzu7Y9vPxvtr/Wj30jO7a/hzYKo/0Ta/0IC/xS07xUm/QJT9DCa/cKf/qDU/av37nEf/ulx71ac3aYT/1Y39AZa/xZ7/uXC/sAu/1XA72cU/yF3/zWp/1aX/lD9zy6O33eg74Rc/ndX9AvT64NL5gvJ3Dax/rl98MDnL4eM74p+741m3tKW7yyx7jOu83zw3dmQ/xqx97rV/joE/tol/zkD/4R3/4ki7uShfdfe/2IQz1vzPycr/ZFj4Kk3/1lQ/3Ne35bc+nzi/8T1/7J57qkd88dw/sqb/4sx/r4Q7x0g/u1J/j8379ppP9Oa/4n9/94M/+sg/8E0/vly305m86yd/O2786SWdm/9EPAoQ4jogAoKhQBK3rFscw0/WBkLmZquz7x2rCW4604yGTypQAVxQdl1Jp8wk9qbDTLbfr/YLD4jHZK9Cufq+gkHbQmn3qALs9IFoJ0d68VbfjPe0BpPX9tQUWDRYaytjdOQnClRFGKk5SVuZFnWV6foKGioo9TAhMPCB18jU+3mFuMaod2lheqsrNOj4m6kzKAu0C2hr95uq69haDVlkNZjZLMsGOVltfY0sxGCgYMKiiHa8JD1FTicOQ1+bpGffRqa87u7cmE5fQ1w9vmodF34b652tatoIGD4qSYIACAAoGJPBYRQidn3gz3vijCM8eu0UaacmTFvGjxYv3rv/gereR18l2zFo+oyRwWRaENm/i5CLAwImdcCQCG5esn5Kg6TjyS6lv3zylc0C6gZnvaUll+F4mDSiVYM6uXm/6JMQzRQIFCs4IUJChANu2bTNgOCB37lwMZ9HizYtXrdu+cOkCxnABAeHChi/cRcu379u4gOkKNiwZcd7FjAv8fVx3sOTClPeuvcw2s+bInQl/1qt6tWLOp1Ozjq1XgevOqc9+za37WgUDDQA0MFCBrFnZxo8rTox8uerizJ9XVg79ufPp0KtbZ449+3Lcu7+DpwTBQIQEEQxAiEhUlESD7Qu+zxYf2/xr9e2vD69/f4oJ5yNMAI5N91VD4CgGspf/HzMKfoJggvxBGCEYDi44IIOeUNjghdBsKFOHHkoYoohFfUhGhhiWOMaJHFrYoosjwhjiiiAiNGMZNpqYohg4qqjjjj7GGCQ2CSRgE5FGFonQkUomedCSTjYJpZBTUlmllVdimaWWW3LZpZdfghmmmGOSWaaZuiXgABJpLgFBBQJUkAoKEsCZ3hZuwiknCmwq4cCbqKRAZwV29vmnngDwuYQDCRAqKKFTLPpoomsS+aSjW1T6JKJqLlGKRJd2agock6bwQKYJyAlqJhCcigKeEJ0Z6ycO7KRACrRys0Q3BniDQnAMLLDAo0rs2isAuNqqBK+8JvtrsMOmsGyux9Yq/4UDC4wFnDfPbnFttsguIa0Bvm4r7BTiogBun9gqEAG5wJqbhLftplttEgmIW6Sz8XqBahI7SQsABMFu85usB5Oxa7IAKLyEBA88cB6qBiwAQG8GS/FwxAYU2bASAY437gMUW+zbEiDzioLHSmwz1sgVX7xFy1isjASvlQLwcskYK8vxkjXzcB6nOZMccxJC8wA0CqYmMAGvEOhstBcKLNDAo6wmEJy7wQ2H7aEIg90FvgsjOq0U57Ga69heoL2n2fcGd8Laay+RdbZlkx1R1WPN/fa/e2tBdxLMUlBk33nbzE3hZPmdLnnnMXS4vI8vxDjiPFhggAV4cw7GBN0oAP9rCucF2E3HHIeduthv040vr1rELDkXUre+LBafmyz7x91gXPvrDjwUlu6T03m372NRIEDmwg6fRPLL23m8APgykMA2EzRfdvXXu52s69mGnF72XTjQDUMoOO0uw6ibrrr7UgjeOdOMkrv5sb0qdP4Uwdnf/dKVPsp0wPtG/rbQPvkBEGC2GyAACrgEBb7OfzkDYNI4xkAHGhB1CCQSBIBnK59csHJI8KBYsEC3+dkpc/YLof6+kACHMEB0pEOBQyCyjaG9L4fH6k31UuEnb/gLCQ6JwBmKdB4JOCRAUxhiEXcIxK9ZTwDBQQ8AjphEJURxiun5YQ+RgDUVpseKBlD/ohK+qLkt8jCIZGGA8iiWCjGS8V5sXJ4P0/i1Kj5kG0Z8yBWPlkfUcVGNjKMiCuDoufNYIEo7UR8AnEYBhTBShzksFvukFSUUiOsEDthG1biQyfUt65IQaFkEYLVJivGMB6PkVSlVZskHfouTqYQlzV6pypYxgFOn7KQUVukNTlHyksfipBJ3Oct0EdOVoUwC73hgzDBYQABfewC2RAccbOVSktrcJje76c1vgjOc4hwnOctpznOiM53qXCc72+nOd8IznvKcJz3rac974jOf+twnP/vpz38CNKACHShBC3oTpiGsAZfzAgUocMdPfM6aBp2oKKYo0RtpECf4Mse0/0xhooxWgwILeChFS0qG82guUAqIpgkpoIAGHAoCFjALTCHQDQvE0RRlsUAqTOGm9HxOAcNpoEsTKbCZWkBNCRCABGYKkczhJqiPbCR5BAABjx5rpjBFFFOdigRq2u9NKhjOA9IyVeCYJalcdQD2HqBQ74wHSCYtqUIq4LUGekMA58ErBYLTwrK0MannYQDPburX9WHLbg1wSAUcKYDkDYyNwRLLAna1ygjYqq96RU9wKlu+cUVWAAv4xk4q+zQeKCRJmXMA8DYHLAHcsIpSXIC7SsuTCCxAioxUwDfm6tsxZE6mY1xferrREJ5sFgkTmGmudnJJ4wJgG+uTE23PwP8NHp6iZNE0nXO1RSTwpUViAJiWcXsDkeDgSl8g3QnjGoBeD7ZRbgrFllhgFaxoEoq9v92vF0bGjcGuz5XrwwsPgtOAtXW3ggKG7niJeIYApYVXDdgJS63aXeduVGCjXS7qyDuuC3MMxIoc1+ho+42xoSUB+ZOAdBPsAAqcJ1765S+NpdAblgotbhLYa28K19QKSsBpH+RJlEzX4wDTkMimqMCBHTlACWQtvWL57iPxVbj2kYdRxgVe4XA75S/3xwBDA9hQg4W9xvpkxx/WoAKw1w1OwbjGcmaZAeRk4Ad0IwJ7JQRKWzivXEEAchU8jwJSweAHWABbuVXzQlLBYl6FMQACIkYsAJanR7GIGbr++eWXE+yqu4VMTi9m5cO2oec1J8kh5FEiWOfs6jthbwKjBQWDs5RoOymkfw0i5Kt7PUJsLQSHlKg1lqjJgFQ4RJhlcJpcfe3sZ0M72tKeNrWrbe1rYzvb2t42t7vt7W+DO9ziHje5y23uc6M73epeN7vbTYYQAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Idiopathic pulmonary fibrosis (IPF) has an older age distribution than either pulmonary Langerhans cell histiocytosis (LCH) or sarcoidosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from King, TE, Jr. Interstitial lung diseases: General approaches. In: Parsons, PE, Heffner, JE, (Eds), Pulmonary and Respiratory Therapy Secrets, Philadelphia, Handley &amp;Belfus, Inc. 1997, p. 234.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_32_18958=[""].join("\n");
var outline_f18_32_18958=null;
var title_f18_32_18959="Osteopenia of prematurity";
var content_f18_32_18959=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52881&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52881&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Osteopenia of prematurity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radiograph of the wrist in an infant with severe osteopenia of prematurity. The major findings are the highly \"washed out\" appearance of the bones of the arm and hand and the cupping and fraying of the distal ends of the long bones (arrow). This appearance is similar to that seen in classical vitamin D deficient rickets in older children.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven A Abrams, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_32_18959=[""].join("\n");
var outline_f18_32_18959=null;
